<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>LOESTRIN 24 FE - norethindrone acetate and ethinyl estradiol, and ferrous fumarate 
			 </strong><br>Physicians Total Care, Inc.<br></p></div>
<h1></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<p class="First">(norethindrone acetate and ethinyl estradiol tablets, USP and 
ferrous fumarate tablets)<br>Ferrous fumarate tablets are not USP for 
dissolution and assay.</p>
<p><span class="Bold">Rx Only</span></p>
<p><span class="Bold">Patients should be counseled that this product does not 
protect against <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> (AIDS) and other sexually transmitted 
diseases.</span></p>
</div>
<div class="Warning">
<a name="section-2"></a><p></p>
<p class="First"><span class="Bold">Cigarette smoking increases the risk of serious cardiovascular 
side effects from oral contraceptive use. This risk increases with age and with 
the extent of smoking (in epidemiologic studies, 15 or more cigarettes per day 
was associated with a significantly increased risk) and is quite marked in women 
over 35 years of age. Women who use oral contraceptives should be strongly 
advised not to smoke.</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Loestrin<span class="Sup">®</span> 24 Fe  provides a dosage regimen 
consisting of 24 white progestogen-estrogen contraceptive tablets and 4 brown 
ferrous fumarate (placebo) tablets. </p>
<p>Each white tablet contains 1 mg norethindrone acetate and 20 mcg ethinyl 
estradiol.<br>Each white tablet also contains the following inactive 
ingredients: acacia, lactose, magnesium stearate, starch, confectioner’s sugar, 
and talc.</p>
<p>Each brown tablet contains ferrous fumarate, microcrystalline cellulose, 
magnesium stearate, povidone, sodium starch glycolate, and compressible sugar. 
The ferrous fumarate tablets do not serve any therapeutic purpose.</p>The structural formulas for the active hormones are:<div class="Figure"><img alt="image of Ethinyl Estradiol chemical structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4cafa90a-9903-40d0-b8be-6ad78018b4b6&amp;name=Ethinyl%20Estradiol%20chemical%20structure.jpg"></div>
<p>Ethinyl Estradiol [19-Norpregna-1,3,5(10)-trien-20-yne-3,17-diol, (17α)-]</p>
<div class="Figure"><img alt="image of Norethaindrone Acetate chemical structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4cafa90a-9903-40d0-b8be-6ad78018b4b6&amp;name=Norethindrone%20Acetate%20chemical%20structure.jpg"></div>
<p>Norethindrone Acetate [19-Norpregn-4-en-20-yn-3-one, 17-(acetyloxy)-, (17α)-]</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Combination oral contraceptives act by suppression of gonadotropins. Although 
the primary mechanism of this action is inhibition of ovulation, other 
alterations include changes in the cervical mucus (which increase the difficulty 
of sperm entry into the uterus) and the endometrium (which reduce the likelihood 
of implantation).</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="section-4"></a><p></p>
<h1>PHARMACOKINETICS</h1>
<a href="#section-"></a>Absorption<p class="First">Norethindrone acetate appears to be completely and rapidly 
deacetylated to norethindrone after oral administration, because the disposition 
of norethindrone acetate is indistinguishable from that of orally administered 
norethindrone. Norethindrone acetate and ethinyl estradiol are rapidly absorbed 
from Loestrin 24 Fe tablets, with maximum plasma concentrations of norethindrone 
and ethinyl estradiol occurring 1 to 4 hours postdose. Both are subject to 
first-pass metabolism after oral dosing, resulting in an absolute 
bioavailability of approximately 64% for norethindrone and 43% for ethinyl 
estradiol. </p>
<p>The plasma norethindrone and ethinyl estradiol pharmacokinetics following 
single- and multiple-dose administrations of Loestrin 24 Fe tablets in 17 
healthy female volunteers are provided in Figures 1 and 2, and Table 1. </p>
<p>Following multiple-dose administration of Loestrin 24 Fe tablets, mean 
maximum concentrations of norethindrone and ethinyl estradiol were increased by 
95% and 27%, respectively, as compared to single-dose administration. Mean 
norethindrone and ethinyl estradiol exposures (AUC values) were increased by 
164% and 51% respectively, as compared to single-dose administration of Loestrin 
24 Fe tablets. </p>
<p>Steady-state with respect to norethindrone was reached by Day 17 and 
steady-state with respect to ethinyl estradiol was reached by Day 13. </p>Mean SHBG concentrations were increased by 150% from baseline (57.5 nmol/L) 
to 144 nmol/L at steady-state.<div class="Figure"><img alt="image of Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4cafa90a-9903-40d0-b8be-6ad78018b4b6&amp;name=figure%201.jpg"></div>
<p><span class="Bold">Figure 1. Mean Plasma Norethindrone Concentration-Time Profiles Following 
Single- and Multiple-Dose Oral Administration of Loestrin 24 Fe Tablets to 
Healthy Female Volunteers under Fasting Condition (n = 17)</span></p>
<div class="Figure"><img alt="image of Figure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4cafa90a-9903-40d0-b8be-6ad78018b4b6&amp;name=figure%202.jpg"></div>
<p><span class="Bold">Figure 2. Mean Plasma Ethinyl Estradiol Concentration-Time Profiles Following 
Single- and Multiple-Dose Oral Administration of Loestrin 24 Fe Tablets to 
Healthy Female Volunteers under Fasting Condition (n = 17)</span></p>
<a name="ic7d2a6ba-a300-44a2-8c4a-4893ab7e89ad"></a><table width="100%">
<caption><span>Table 1. Summary of Norethindrone (NE) and Ethinyl Estradiol (EE) Pharmacokinetics Following Single- and Multiple-Dose Oral Administration of Loestrin 24 Fe Tablets to Healthy Female Volunteers under Fasting Condition (n = 17)</span></caption>
<tbody class="Headless">
<tr class="First">
<td><br></td>
<td><br></td>
<td>Arithmetic<br>
</td>
<td>Mean* (%CV)<br>
</td>
<td>by Pharmacokinetic<br>
</td>
<td>Parameter<br>
</td>
<td><br></td>
<td><br></td>
</tr>
<tr>
<td>Regimen<br><br>
</td>
<td>Analyte<br><br>
</td>
<td>
<p class="First">C<span class="Sub">max</span></p>(pg/mL)</td>
<td>
<p class="First">t<span class="Sub">max</span></p>(hr)</td>
<td>
<p class="First">AUC<span class="Sub">(0-24)</span></p>(pg/mL•h)</td>
<td>
<p class="First">C<span class="Sub">min</span></p>(pg/mL)</td>
<td>
<p class="First">t<span class="Sub">½</span></p>(hr)</td>
<td>
<p class="First">C<span class="Sub">avg</span></p>(pg/mL)</td>
</tr>
<tr>
<td><br></td>
<td>NE<br>
</td>
<td>8420 (31)<br>
</td>
<td>1.0 (0.7-4.0)<br>
</td>
<td>33390 (40)<br>
</td>
<td>--<br>
</td>
<td>--<br>
</td>
<td>--<br>
</td>
</tr>
<tr>
<td>Day 1 (Single Dose)<br>
</td>
<td>EE<br>
</td>
<td>64.5 (27)<br>
</td>
<td>1.3 (0.7-4.0)<br>
</td>
<td>465.4 (26)<br>
</td>
<td>--<br>
</td>
<td>--<br>
</td>
<td>--<br>
</td>
</tr>
<tr>
<td><br></td>
<td>SHBG<br>
</td>
<td>--<br>
</td>
<td>--<br>
</td>
<td>--<br>
</td>
<td>57.5 (37)<span class="Bold">†</span>
</td>
<td>--<br>
</td>
<td>--<br>
</td>
</tr>
<tr>
<td><br></td>
<td>NE<br>
</td>
<td>16400 (26)<br>
</td>
<td>1.3 (0.7-4.0)<br>
</td>
<td>88160 (30)<br>
</td>
<td>880 (51)<br>
</td>
<td>8.4<br>
</td>
<td>3670 (30)<br>
</td>
</tr>
<tr>
<td>Day 24 (Multiple Dose)<br>
</td>
<td>EE<br>
</td>
<td>81.9 (24)<br>
</td>
<td>1.7 (1.0-2.0)<br>
</td>
<td>701.3 (28)<br>
</td>
<td>11.4 (43)<br>
</td>
<td>14.5<br>
</td>
<td>29.2 (28)<br>
</td>
</tr>
<tr>
<td><br></td>
<td>SHBG<br>
</td>
<td>--<br>
</td>
<td>--<br>
</td>
<td>--<br>
</td>
<td>144 (24)<br>
</td>
<td>--<br>
</td>
<td>--<br>
</td>
</tr>
<tr class="Last">
<td><br></td>
<td><br></td>
<td><br></td>
<td><br></td>
<td><br></td>
<td><br></td>
<td><br></td>
<td><br></td>
</tr>
</tbody>
</table>C<span class="Sub">max</span> = Maximum plasma concentration; t<span class="Sub">max</span> = Time of C<span class="Sub">max</span> ; C<span class="Sub">min</span> = minimum plasma concentration at steady-state ; AUC<span class="Sub">(0-24)</span> = Area under plasma concentration versus time curve from 
0 to 24 hours ; t<span class="Sub">½</span> = Apparent first-order terminal 
elimination half-life ; C<span class="Sub">avg</span> = Average plasma 
concentration = AUC<span class="Sub">(0–24)/24</span> %CV = Coefficient of 
Variation (%); SHBG = <span class="product-label-link" type="condition" conceptid="4206320" conceptname="Sex steroid binding globulin">Sex Hormone Binding Globulin</span> (nmol/L)<br>*  The harmonic mean (0.693/mean apparent elimination rate constant) is reported 
for t<span class="Sub">½</span>, and the median (range) is reported for t<span class="Sub">max</span>.<br>†  The SHBG concentration reported here is the pre-dose concentration.  <br><br><br><p>Effect of Food: Loestrin 24 Fe tablets may be administered without regard to 
meals. A single-dose administration of Loestrin 24 Fe tablet with food decreased 
the maximum concentration of norethindrone by 11% and increased the extent of 
absorption by 27% and decreased the maximum concentration of ethinyl estradiol 
by 30% but not the extent of absorption. </p>
<a href="#section-"></a><a href="#section-"></a><a href="#section-"></a>Distribution<p>Volume of distribution of norethindrone and ethinyl estradiol 
ranges from 2 to 4 L/kg. Plasma protein binding of both steroids is extensive 
(&gt;95%); norethindrone binds to both albumin and SHBG, whereas ethinyl 
estradiol binds only to albumin. Although ethinyl estradiol does not bind to 
SHBG, it induces SHBG synthesis.</p>
<a href="#section-"></a><a href="#section-"></a><a href="#section-"></a>Metabolism<p>Norethindrone undergoes extensive biotransformation, primarily 
via reduction, followed by sulfate and glucuronide conjugation. The majority of 
metabolites in the circulation are sulfates, with glucuronides accounting for 
most of the urinary metabolites. </p>
<p>Ethinyl estradiol is also extensively metabolized, both by oxidation and by 
conjugation with sulfate and glucuronide. Sulfates are the major circulating 
conjugates of ethinyl estradiol and glucuronides predominate in urine. The 
primary oxidative metabolite is 2-hydroxy ethinyl estradiol, formed by the 
CYP3A4 isoform of cytochrome P450. Part of the first-pass metabolism of ethinyl 
estradiol is believed to occur in gastrointestinal mucosa. Ethinyl estradiol may 
undergo enterohepatic circulation.</p>
<a href="#section-"></a><a href="#section-"></a><a href="#section-"></a>Excretion<p>Norethindrone and ethinyl estradiol are excreted in both urine 
and feces, primarily as metabolites. Plasma clearance values for norethindrone 
and ethinyl estradiol are similar (approximately 0.4 L/hr/kg). Steady-state 
elimination half-lives of norethindrone and ethinyl estradiol following 
administration of Loestrin 24 Fe tablets are approximately 8 hours and 14 hours, 
respectively.</p>
<a href="#section-"></a><a href="#section-"></a><a href="#section-"></a>Special Populations<p><span class="Bold">Race. </span>The effect of race on the 
disposition of norethindrone and ethinyl estradiol after Loestrin 24 Fe 
administration has not been evaluated.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span>. </span>The effect of <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> on 
the disposition of norethindrone and ethinyl estradiol after Loestrin 24 Fe 
administration has not been evaluated. In premenopausal women with chronic renal 
failure undergoing peritoneal dialysis who received multiple doses of an oral 
contraceptive containing ethinyl estradiol and norethindrone, plasma ethinyl 
estradiol concentrations were higher and norethindrone concentrations were 
unchanged compared to concentrations in premenopausal women with normal renal 
function.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span>.</span> The effect of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span> 
on the disposition of norethindrone and ethinyl estradiol after Loestrin 24 Fe 
administration has not been evaluated. However, ethinyl estradiol and 
norethindrone may be poorly metabolized in patients with impaired liver 
function.</p>
<a href="#section-"></a><a href="#section-"></a><a href="#section-"></a>Drug-Drug Interactions<p>See <span class="Bold"><a href="#section-"> PRECAUTIONS</a></span> 
section—<span class="Bold"><a href="#section-"> DRUG 
INTERACTIONS</a></span></p>
<br>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-5"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Loestrin 24 Fe is indicated for the prevention of pregnancy in 
women who elect to use oral contraceptives as a method of contraception.</p>
<p>Oral contraceptives are highly effective. Table 2 lists the typical unplanned 
pregnancy rates for users of combination oral contraceptives and other methods 
of contraception. The efficacy of these contraceptive methods, except 
sterilization, the IUD, and the Norplant<span class="Sup">®</span> system, depends 
upon the reliability with which they are used. Correct and consistent use of 
methods can result in lower failure rates.</p>
<a name="i97c37dd4-ca40-4571-84ed-0fc47406a51e"></a><table width="100%">
<caption><span>TABLE 2 Percentage of women experiencing an <span class="product-label-link" type="condition" conceptid="4307820" conceptname="Unplanned pregnancy">unintended pregnancy</span> during the first year of typical use and the first year of perfect use of contraception and the percentage continuing use at the end of the first year. United States.</span></caption>
<tbody class="Headless">
<tr class="First">
<td><br></td>
<td>% of Women<br>Unintended<br>the First Year<br>
</td>
<td>Experiencing an<br>Pregnancy with<br>of Use<br>
</td>
<td>% of Women Continuing Use<br>at One Year*<br>
</td>
</tr>
<tr>
<td>Method<br>(1)<br>
</td>
<td>Typical Use†<br>(2)<br>
</td>
<td>Perfect Use‡<br>(3)<br>
</td>
<td>
<br>(4)<br>
</td>
</tr>
<tr>
<td>Chance§</td>
<td>85<br>
</td>
<td>85<br>
</td>
<td><br></td>
</tr>
<tr>
<td>Spermicides¶</td>
<td>26<br>
</td>
<td>6<br>
</td>
<td>40<br>
</td>
</tr>
<tr>
<td>Periodic abstinence</td>
<td>25<br>
</td>
<td><br></td>
<td>63<br>
</td>
</tr>
<tr>
<td>  Calendar<br>
</td>
<td><br></td>
<td>9<br>
</td>
<td><br></td>
</tr>
<tr>
<td>  Ovulation Method<br>
</td>
<td><br></td>
<td>3<br>
</td>
<td><br></td>
</tr>
<tr>
<td>  Sympto-thermal#<br>
</td>
<td><br></td>
<td>2<br>
</td>
<td><br></td>
</tr>
<tr>
<td>  Post-Ovulation<br>
</td>
<td><br></td>
<td>1<br>
</td>
<td><br></td>
</tr>
<tr>
<td>CapÞ</td>
<td><br></td>
<td><br></td>
<td><br></td>
</tr>
<tr>
<td>  Parous Women<br>
</td>
<td>40<br>
</td>
<td>26<br>
</td>
<td>42<br>
</td>
</tr>
<tr>
<td>  Nulliparous Women<br>
</td>
<td>20<br>
</td>
<td>9<br>
</td>
<td>56<br>
</td>
</tr>
<tr>
<td>Sponge<br>
</td>
<td><br></td>
<td><br></td>
<td><br></td>
</tr>
<tr>
<td>  Parous Women<br>
</td>
<td>40<br>
</td>
<td>20<br>
</td>
<td>42<br>
</td>
</tr>
<tr>
<td>  Nulliparous Women<br>
</td>
<td>20<br>
</td>
<td>9<br>
</td>
<td>56<br>
</td>
</tr>
<tr>
<td>DiaphragmÞ</td>
<td>20<br>
</td>
<td>6<br>
</td>
<td>56<br>
</td>
</tr>
<tr>
<td>Withdrawal<br>
</td>
<td>19<br>
</td>
<td>4<br>
</td>
<td><br></td>
</tr>
<tr>
<td>Condomß</td>
<td><br></td>
<td><br></td>
<td><br></td>
</tr>
<tr>
<td>  Female (reality)<br>
</td>
<td>21<br>
</td>
<td>5<br>
</td>
<td>56<br>
</td>
</tr>
<tr>
<td>  Male<br>
</td>
<td>14<br>
</td>
<td>3<br>
</td>
<td>61<br>
</td>
</tr>
<tr>
<td>Pill<br>
</td>
<td>5<br>
</td>
<td><br></td>
<td>71<br>
</td>
</tr>
<tr>
<td>  Progestin only<br>
</td>
<td><br></td>
<td>0.5<br>
</td>
<td><br></td>
</tr>
<tr>
<td>  Combined<br>
</td>
<td><br></td>
<td>0.1<br>
</td>
<td><br></td>
</tr>
<tr>
<td>IUD<br>
</td>
<td><br></td>
<td><br></td>
<td><br></td>
</tr>
<tr>
<td>  Progesterone T<br>
</td>
<td>2.0<br>
</td>
<td>1.5<br>
</td>
<td>81<br>
</td>
</tr>
<tr>
<td>  Copper T 380A<br>
</td>
<td>0.8<br>
</td>
<td>0.6<br>
</td>
<td>78<br>
</td>
</tr>
<tr>
<td>  LNg 20<br>
</td>
<td>0.1<br>
</td>
<td>0.1<br>
</td>
<td>81<br>
</td>
</tr>
<tr>
<td>Depo-Provera<span class="Sup">®</span>
</td>
<td>0.3<br>
</td>
<td>0.3<br>
</td>
<td>70<br>
</td>
</tr>
<tr>
<td>Norplant<span class="Sup">®</span> and Norplant<span class="Sup">®</span> 2</td>
<td>0.05<br>
</td>
<td>0.05<br>
</td>
<td>88<br>
</td>
</tr>
<tr>
<td>Female Sterilization<br>
</td>
<td>0.5<br>
</td>
<td>0.5<br>
</td>
<td>100<br>
</td>
</tr>
<tr class="Last">
<td>Male Sterilization<br>
</td>
<td>0.15<br>
</td>
<td>0.10<br>
</td>
<td>100<br>
</td>
</tr>
</tbody>
</table>
<span class="Bold">Emergency Contraceptive Pills</span>: Treatment initiated 
within 72 hours after unprotected intercourse <br>reduces risk of pregnancy by at 
least 75% à<br><span class="Bold">Lactational <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">Amenorrhea</span> Method</span>: LAM is a highly 
effective, <span class="Italics">temporary</span> method of contraception è<br>Source: Trussell J, Stewart F, Contraceptive Efficacy. In Hatcher RA, Trussell 
J, Stewart F, Cates W, <br>Stewart GK, Kowal D, Guest F, <span class="Italics">Contraceptive Technology:</span><span class="Italics">Seventeenth 
Revised Edition</span>. <br>New York, NY: Irvington Publishers, 1998.<br>*  Among couples attempting to avoid pregnancy, the percentage who continue to use 
a method for one year <br>†  Among <span class="Italics">typical</span> couples who initiate use of a method 
(not necessarily for the first time), the percentage who experience an 
accidental pregnancy during the first year if they do not stop use for any other 
reason <br>‡  Among couples who initiate use of a method (not necessarily for the first time) 
and who use it perfectly (both consistently <br>and correctly), the percentage who 
experience an accidental pregnancy during the first year if they do not stop use 
for any other reason <br>§  The percentage of women becoming pregnant noted in columns (2) and (3) are based 
on data from populations where contraception is not used and from women who 
cease using contraception in order to become pregnant. Among such <br>populations, 
about 89% became pregnant in one year. This estimate was lowered slightly (to 
85%) to represent the percentage <br>that would become pregnant within one year 
among women now relying on reversible methods of contraception if they abandon 
contraception altogether <br>¶  Foams, creams, gels, vaginal suppositories and vaginal film <br>#  Cervical mucous (ovulation) method supplemented by calendar in the preovulatory 
and basal body temperature in the postovulatory phases <br>Þ  With spermicidal cream or jelly  <br>ß  Without spermicides <br>à  The treatment schedule is one dose within 72 hours after unprotected intercourse 
and a second dose 12 hours after the first <br>dose. The Food and Drug 
Administration has declared the following brands of oral contraceptives to be 
safe and effective for emergency contraception: Ovral<span class="Sup">®</span> (1 
dose is 2 white pills), Alesse<span class="Sup">®</span> (1 dose is 5 pink pills), 
Nordette<span class="Sup">®</span> or Levlen<span class="Sup">®</span> (1 dose is 2 
light orange pills), Lo/Ovral<span class="Sup">®</span> (1 dose is 4 white pills), 
Triphasil<span class="Sup">®</span> or Tri-Levlen<span class="Sup">®</span> (1 dose 
is 4 yellow pills)<br>è  <br>However, to maintain effective protection against pregnancy, another method 
of contraception must be used as soon as menstruation resumes, the frequency or 
duration of breastfeeds is reduced, bottle feeds are introduced or the baby 
reaches six months of age <br><br><a href="http://"></a>Clinical Studies <p>In a clinical study, 743 women, 18 to 45 years of age, were 
treated with Loestrin 24 Fe for up to six 28-day cycles providing a total of 
3,823 treatment-cycles of exposure. A total of 583 women completed 6 cycles of 
treatment. There were a total of 5 on-treatment pregnancies in 3,565 treatment 
cycles during which no backup contraception was used. The Pearl Index for 
Loestrin 24 Fe was 1.82.</p>
<br>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-6"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Oral contraceptives should not be used in women who currently 
have the following conditions:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">Thrombophlebitis</span> or thromboembolic disorders 
</li>
<li>A past history of deep vein <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span> or thromboembolic disorders 
</li>
<li>Cerebrovascular or <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> (current or history) 
</li>
<li><span class="product-label-link" type="condition" conceptid="4281749" conceptname="Heart valve disorder">Valvular heart disease</span> with thrombogenic complications 
</li>
<li>Severe <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> 
</li>
<li><span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> with vascular involvement 
</li>
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headaches</span> with focal neurological symptoms 
</li>
<li>Major surgery with prolonged immobilization 
</li>
<li>Known or suspected carcinoma of the breast or personal history of breast 
cancer 
</li>
<li>Carcinoma of the endometrium or other known or suspected estrogen-dependent 
neoplasia 
</li>
<li>Undiagnosed abnormal genital <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> 
</li>
<li><span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">Cholestatic jaundice</span> of pregnancy or <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> with prior pill use 
</li>
<li><span class="product-label-link" type="condition" conceptid="4301500" conceptname="Liver cell adenoma">Hepatic adenomas</span> or carcinomas, or active liver disease 
</li>
<li>Known or suspected pregnancy 
</li>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to any component of this product </li>
</ul>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-7"></a><p></p>
<h1>WARNINGS</h1>
<a href="http://"></a><p class="First"><span class="Bold">Cigarette smoking increases the risk of serious 
cardiovascular side effects from oral contraceptive use. This risk increases 
with age and with the extent of smoking (in epidemiologic studies, 15 or more 
cigarettes per day was associated with a significantly increased risk) and is 
quite marked in women over 35 years of age. Women who use oral contraceptives 
should be strongly advised not to smoke.</span></p>
<a href="http://"></a><a href="http://"></a><p>The use of oral contraceptives is associated with increased risk 
of several serious conditions including venous and arterial thrombotic and 
<span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic events</span> (such as <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span>, and 
<span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>), <span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">hepatic neoplasia</span>, <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">gallbladder disease</span>, and <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, although the 
risk of serious morbidity or mortality is very small in healthy women without 
underlying risk factors. The risk of morbidity and mortality increases 
significantly in the presence of other underlying risk factors such as certain 
inherited <span class="product-label-link" type="condition" conceptid="4125650" conceptname="Thrombophilia">thrombophilias</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemias</span>, <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span> and 
<span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>.</p>
<p>Practitioners prescribing oral contraceptives should be familiar with the 
following information relating to these risks. The information contained in this 
package insert is principally based on studies carried out in patients who used 
oral contraceptives with higher formulations of estrogens and progestogens than 
those in common use today. The effect of long-term use of the oral 
contraceptives with lower formulations of both estrogens and progestogens 
remains to be determined.</p>
<p>Throughout this labeling, epidemiological studies reported are of two types: 
retrospective or case control studies and prospective or cohort studies. Case 
control studies provide a measure of the relative risk of a disease, namely, a 
<span class="Italics">ratio</span> of the incidence of a disease among oral 
contraceptive users to that among nonusers. The relative risk does not provide 
information on the actual clinical occurrence of a disease. Cohort studies 
provide a measure of attributable risk, which is the <span class="Italics">difference</span> in the incidence of disease between oral 
contraceptive users and nonusers. The attributable risk does provide information 
about the actual occurrence of a disease in the population. For further 
information, the reader is referred to a text on epidemiological methods.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>1. THROMBOEMBOLIC DISORDERS AND OTHER VASCULAR 
PROBLEMS<a href="http://"></a><a href="http://"></a><a href="http://"></a><span class="Bold">a. <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span></span><p>An increased risk of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> has been attributed to 
oral contraceptive use. This risk is primarily in smokers or women with other 
underlying risk factors for <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> such as <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, 
<span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span>, <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">morbid obesity</span>, and <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. The relative risk of heart 
attack for current oral contraceptive users has been estimated to be two to six. 
The risk is very low under the age of 30.</p>Smoking in combination with oral contraceptive use has been shown to 
contribute substantially to the incidence of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarctions</span> in women in 
their mid-thirties or older, with smoking accounting for the majority of excess 
cases. Mortality rates associated with circulatory disease have been shown to 
increase substantially in smokers over the age of 35 and <span class="product-label-link" type="condition" conceptid="4222303" conceptname="Non-smoker">nonsmokers</span> over the age 
of 40 (Figure 3) among women who use oral contraceptives.<div class="Figure"><img alt="image of figure 3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4cafa90a-9903-40d0-b8be-6ad78018b4b6&amp;name=figure%203.jpg"></div>
<p></p>
<p>FIGURE 3. CIRCULATORY DISEASE MORTALITY RATES FOR 
100,000 WOMEN-YEARS BY AGE, SMOKING STATUS AND ORAL CONTRACEPTIVE USE</p>
<p>Layde PM, Beral V. <span class="Italics">Lancet</span> 1981;1:541-546.</p>
<p>Oral contraceptives may compound the effects of well-known risk factors, such 
as <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemias</span>, age, and <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>. In particular, 
some progestogens are known to decrease HDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and cause glucose 
intolerance, while estrogens may create a state of <span class="product-label-link" type="condition" conceptid="4307509" conceptname="Hyperinsulinism">hyperinsulinism</span>. Oral 
contraceptives have been shown to increase blood pressure among users (see 
section <span class="Bold"><a href="#i4i_section_id_330188de-9ee8-464c-9ab0-46c97122a7c5">9 </a></span>in 
<span class="Bold"><a href="#i4i_warnings_id_732d4fa2-5aa3-499f-9c15-613a3e67732a">WARNINGS</a></span>). 
Such increases in risk factors have been associated with an increased risk of 
heart disease and the risk increases with the number of risk factors present. 
Oral contraceptives must be used with caution in women with cardiovascular 
disease risk factors.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a><span class="Bold">b. <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">Thromboembolism</span></span><p>An increased risk of thromboembolic and thrombotic disease 
associated with the use of oral contraceptives is well established. Case control 
studies have found the relative risk of users compared to non-users to be 3 for 
the first episode of superficial <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">venous thrombosis</span>, 4 to 11 for deep vein 
<span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> or <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, and 1.5 to 6 for women with predisposing 
conditions for venous thromboembolic disease. Cohort studies have shown the 
relative risk to be somewhat lower, about 3 for new cases and about 4.5 for new 
cases requiring hospitalization. The risk of thromboembolic disease due to oral 
contraceptives is not related to length of use and disappears after pill use is 
stopped.</p>
<p>A two- to four-fold increase in relative risk of postoperative thromboembolic 
complications has been reported with the use of oral contraceptives. The 
relative risk of <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">venous thrombosis</span> in women who have predisposing conditions is 
twice that of women without such medical conditions. If feasible, oral 
contraceptives should be discontinued at least four weeks prior to and for two 
weeks after elective surgery of a type associated with an increase in risk of 
<span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span> and during and following prolonged immobilization. Since the 
immediate postpartum period is also associated with an increased risk of 
<span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span>, oral contraceptives should be started no earlier than four to 
six weeks after delivery in women who elect not to breastfeed.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a><span class="Bold">c. Cerebrovascular diseases</span><p>Oral contraceptives have been shown to increase both the relative 
and attributable risk of cerebrovascular events (thrombotic and hemorrhagic 
<span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span>) although, in general, the risk is greatest among older (&gt;35 years), 
hypertensive women who also smoke. <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> was found to be a risk factor 
for both users and nonusers, for both types of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span>, while smoking interacted 
to increase the risk for <span class="product-label-link" type="condition" conceptid="4046362" conceptname="Hemorrhagic cerebral infarction">hemorrhagic strokes</span>.</p>
<p>In a large study, the relative risk of <span class="product-label-link" type="condition" conceptid="4159140" conceptname="Thrombotic stroke">thrombotic strokes</span> has been shown to 
range from 3 for normotensive users to 14 for users with severe <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. 
The relative risk of <span class="product-label-link" type="condition" conceptid="4046362" conceptname="Hemorrhagic cerebral infarction">hemorrhagic stroke</span> is reported to be 1.2 for <span class="product-label-link" type="condition" conceptid="4222303" conceptname="Non-smoker">nonsmokers</span> who 
used oral contraceptives, 2.6 for smokers who did not use oral contraceptives, 
7.6 for smokers who used oral contraceptives, 1.8 for normotensive users and 
25.7 for users with severe <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. The attributable risk is also greater 
in older women. Oral contraceptives also increase the risk for <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> in women 
with other underlying risk factors such as certain inherited or acquired 
<span class="product-label-link" type="condition" conceptid="4125650" conceptname="Thrombophilia">thrombophilias</span>, <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemias</span>, and <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>. Women with <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> (particularly 
<span class="product-label-link" type="condition" conceptid="381549" conceptname="Migraine with aura">migraine with aura</span>) who take combination oral contraceptives may be at an 
increased risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a><span class="Bold">d. Dose-related risk of vascular 
disease from oral contraceptives</span><p>A positive association has been observed between the amount of 
estrogen and progestogen in oral contraceptives and the risk of vascular 
disease. A decline in serum high-density lipoproteins (HDL) has been reported 
with many progestational agents. A decline in serum high-density lipoproteins 
has been associated with an increased incidence of <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">ischemic heart disease</span>. 
Because estrogens increase HDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, the net effect of an oral 
contraceptive depends on a balance achieved between doses of estrogen and 
progestogen and the nature and absolute amount of progestogens used in the 
contraceptive. The amount of both hormones should be considered in the choice of 
an oral contraceptive.</p>
<p>Minimizing exposure to estrogen and progestogen is in keeping with good 
principles of therapeutics. For any particular estrogen/progestogen combination, 
the dosage regimen prescribed should be one which contains the least amount of 
estrogen and progestogen that is compatible with a low failure rate and the 
needs of the individual patient. New acceptors of oral contraceptive agents 
should be started on preparations containing the lowest estrogen content which 
is judged appropriate for the individual patient.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a><span class="Bold">e. Persistence of risk of vascular 
disease  </span><p>There are two studies which have shown persistence of risk of 
vascular disease for ever-users of oral contraceptives. In a study in the United 
States, the risk of developing <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> after discontinuing oral 
contraceptives persisted for at least 9 years for women 40 to 49 years old who 
had used oral contraceptives for five or more years but this increased risk was 
not demonstrated in other age groups. In another study in Great Britain, the 
risk of developing cerebrovascular disease persisted for at least 6 years after 
discontinuation of oral contraceptives, although excess risk was very small. 
However, both studies were performed with oral contraceptive formulations 
containing 50 micrograms or higher of estrogens.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8"></a><p></p>
<a href="http://"></a>2. ESTIMATES OF MORTALITY FROM CONTRACEPTIVE USE<p class="First">One study gathered data from a variety of sources which have 
estimated the mortality rate associated with different methods of contraception 
at different ages (Table 3).</p>
<a name="i4aa68986-49b2-4df5-86e3-0f9de34ae523"></a><table width="100%">
<caption><span>TABLE 3 ANNUAL NUMBER OF BIRTH-RELATED OR METHOD-RELATED <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">DEATHS</span> ASSOCIATED WITH CONTROL OF FERTILITY PER 100,000 NONSTERILE WOMEN, BY FERTILITY CONTROL METHOD ACCORDING TO AGE</span></caption>
<tbody class="Headless">
<tr class="First">
<td><br></td>
<td><br></td>
<td><br></td>
<td>
<span class="Bold">AGE</span><br>
</td>
<td><br></td>
<td><br></td>
<td><br></td>
</tr>
<tr>
<td><span class="Bold">Method of control<br>and outcome<br></span></td>
<td><span class="Bold">15-19<br><br></span></td>
<td><span class="Bold">20-24<br><br></span></td>
<td><span class="Bold">25-29<br><br></span></td>
<td><span class="Bold">30-34<br><br></span></td>
<td><span class="Bold">35-39<br><br></span></td>
<td><span class="Bold">40-44<br><br></span></td>
</tr>
<tr>
<td>No fertility control methods<a href="#footnote-13">*</a>
</td>
<td>7.0<br>
</td>
<td>7.4<br>
</td>
<td>9.1<br>
</td>
<td>14.8<br>
</td>
<td>25.7<br>
</td>
<td>28.2<br>
</td>
</tr>
<tr>
<td>Oral contraceptives<br><span class="product-label-link" type="condition" conceptid="4222303" conceptname="Non-smoker">nonsmoker</span><a href="#footnote-14">†</a><br>
</td>
<td>0.3<br><br>
</td>
<td>0.5<br><br>
</td>
<td>0.9<br><br>
</td>
<td>1.9<br><br>
</td>
<td>13.8<br><br>
</td>
<td>31.6<br><br>
</td>
</tr>
<tr>
<td>Oral contraceptives<br>smoker<a href="#footnote-14">†</a><br>
</td>
<td>2.2<br><br>
</td>
<td>3.4<br><br>
</td>
<td>6.6<br><br>
</td>
<td>13.5<br><br>
</td>
<td>51.1<br><br>
</td>
<td>117.2<br><br>
</td>
</tr>
<tr>
<td>IUD<a href="#footnote-14">†</a>
</td>
<td>0.8<br>
</td>
<td>0.8<br>
</td>
<td>1.0<br>
</td>
<td>1.0<br>
</td>
<td>1.4<br>
</td>
<td>1.4<br>
</td>
</tr>
<tr>
<td>Condom<a href="#footnote-13">*</a>
</td>
<td>1.1<br>
</td>
<td>1.6<br>
</td>
<td>0.7<br>
</td>
<td>0.2<br>
</td>
<td>0.3<br>
</td>
<td>0.4<br>
</td>
</tr>
<tr>
<td>Diaphragm/spermicide<a href="#footnote-13">*</a>
</td>
<td>1.9<br>
</td>
<td>1.2<br>
</td>
<td>1.2<br>
</td>
<td>1.3<br>
</td>
<td>2.2<br>
</td>
<td>2.8<br>
</td>
</tr>
<tr class="Last">
<td>Periodic abstinence<a href="#footnote-13">*</a>
</td>
<td>2.5<br>
</td>
<td>1.6<br>
</td>
<td>1.6<br>
</td>
<td>1.7<br>
</td>
<td>2.9<br>
</td>
<td>3.6<br>
</td>
</tr>
</tbody>
</table>Ory HW. <span class="Italics">Family Planning Perspectives</span> 
1983; 15:57-63.<br><a href="http://SPLForm_DrugListing.xhtml#footnote-13">*</a>  <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> are birth related<br><a href="http://SPLForm_DrugListing.xhtml#footnote-14">†</a>  <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> are method related<br><br><p>These estimates include the combined risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> associated with 
contraceptive methods plus the risk attributable to pregnancy in the event of 
method failure. Each method of contraception has its specific benefits and risk. 
The study concluded that with the exception of oral contraceptive users 35 and 
older who smoke and 40 and older who do not smoke, mortality associated with all 
methods of birth control is low and below that associated with childbirth.</p>
<p>The observation of a possible increase in risk of mortality with age for oral 
contraceptive users is based on data gathered in the 1970s but not reported 
until 1983. However, current clinical practice involves the use of lower 
estrogen dose formulations combined with careful restriction of oral 
contraceptive use to women who do not have the various risk factors listed in 
this labeling.</p>
<p>Because of these changes in practice and, also, because of some limited new 
data which suggest that the risk of cardiovascular disease with the use of oral 
contraceptives may now be less than previously observed, the Fertility and 
Maternal Health Drugs Advisory Committee was asked to review the topic in 1989. 
The Committee concluded that although cardiovascular disease risk may be 
increased with oral contraceptive use after age 40 in healthy nonsmoking women 
(even with the newer low-dose formulations), there are greater potential health 
risks associated with pregnancy in older women and with the alternative surgical 
and medical procedures which may be necessary if such women do not have access 
to effective and acceptable means of contraception.</p>
<p>Therefore, the Committee recommended that the benefits of oral contraceptive 
use by healthy nonsmoking women over 40 may outweigh the possible risks. Of 
course, older women, as all women who take oral contraceptives, should take the 
lowest possible dose formulation that is effective and meets the individual 
patient needs.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>3. CARCINOMA OF THE REPRODUCTIVE ORGANS AND 
BREASTS<p>Numerous epidemiological studies have been performed on the 
incidence of breast, endometrial, ovarian, and cervical cancer in women using 
oral contraceptives. Although the risk of breast cancer may be slightly 
increased among current users of oral contraceptives (RR = 1.24), this excess 
risk decreases over time after oral contraceptive discontinuation and by 10 
years after cessation the increased risk disappears. The risk does not increase 
with duration of use, and no relationships have been found with dose or type of 
steroid. The patterns of risk are also similar regardless of a woman's 
reproductive history or her family breast cancer history. The subgroup for whom 
risk has been found to be significantly elevated is women who first used oral 
contraceptives before age 20, but because breast cancer is so rare at these 
young ages, the number of cases attributable to this early oral contraceptive 
use is extremely small. Breast cancers diagnosed in current or previous oral 
contraceptive users tend to be less advanced clinically than in never-users. 
Women who currently have or have had breast cancer should not use oral 
contraceptives because breast cancer is a hormone-sensitive tumor.</p>
<p>Some studies suggest that oral contraceptive use has been associated with an 
increase in the risk of <span class="product-label-link" type="condition" conceptid="198572" conceptname="Cervical intraepithelial neoplasia">cervical intraepithelial neoplasia</span> or invasive cervical 
cancer in some populations of women. However, there continues to be controversy 
about the extent to which such findings may be due to differences in sexual 
behavior and other factors.</p>
<p>In spite of many studies of the relationship between oral contraceptive use 
and breast cancer and cervical cancers, a cause-and-effect relationship has not 
been established.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>4. <span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">HEPATIC NEOPLASIA</span><p>Benign <span class="product-label-link" type="condition" conceptid="4301500" conceptname="Liver cell adenoma">hepatic adenomas</span> are associated with oral contraceptive 
use, although their occurrence is rare in the United States. Indirect 
calculations have estimated the attributable risk to be in the range of 3.3 
cases/100,000 for users, a risk that increases after four or more years of use. 
Rupture of <span class="product-label-link" type="condition" conceptid="4301500" conceptname="Liver cell adenoma">hepatic adenomas</span> may cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> through intra-abdominal 
<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>.</p>
<p>Studies from Britain have shown an increased risk of developing 
hepatocellular carcinoma in long-term (&gt;8 years) oral contraceptive users. 
However, these cancers are extremely rare in the U.S. and the attributable risk 
(the excess incidence) of liver cancers in oral contraceptive users approaches 
less than one per million users.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>5. OCULAR LESIONS<p>There have been clinical case reports of retinal <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> 
associated with the use of oral contraceptives that may lead to partial or 
complete <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span>. Oral contraceptives should be discontinued if there is 
unexplained partial or complete <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span>; onset of <span class="product-label-link" type="condition" conceptid="436700" conceptname="Exophthalmos">proptosis</span> or <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>; 
<span class="product-label-link" type="condition" conceptid="4308632" conceptname="Optic disc edema">papilledema</span>; or retinal vascular lesions. Appropriate diagnostic and therapeutic 
measures should be undertaken immediately.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>6. ORAL CONTRACEPTIVE USE BEFORE OR DURING EARLY 
PREGNANCY<p>Extensive epidemiological studies have revealed no increased risk 
of <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> in women who have used oral contraceptives prior to pregnancy. 
Studies also do not suggest a teratogenic effect, particularly in so far as 
cardiac anomalies and <span class="product-label-link" type="condition" conceptid="73307" conceptname="Transverse deficiency of lower limb">limb reduction defects</span> are concerned, when taken 
inadvertently during early pregnancy (see <span class="Bold"><a href="#i4i_contraindications_id_27afe00c-b408-4fd7-b8a5-228c03e543a3">CONTRAINDICATIONS 
</a></span>section).</p>
<p>The administration of oral contraceptives to induce <span class="product-label-link" type="condition" conceptid="4161407" conceptname="Withdrawal bleeding">withdrawal bleeding</span> 
should not be used as a test for pregnancy. Oral contraceptives should not be 
used during pregnancy to treat threatened or habitual abortion.</p>
<p>It is recommended that for any patient who has missed two consecutive 
periods, pregnancy should be ruled out. If the patient has not adhered to the 
prescribed schedule, the possibility of pregnancy should be considered at the 
time of the first missed period. Oral contraceptive use should be discontinued 
if pregnancy is confirmed.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>7. <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">GALLBLADDER DISEASE</span><p>Earlier studies have reported an increased lifetime relative risk 
of gallbladder surgery in users of oral contraceptives and estrogens. More 
recent studies, however, have shown that the relative risk of developing 
<span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">gallbladder disease</span> among oral contraceptive users may be minimal. The recent 
findings of minimal risk may be related to the use of oral contraceptive 
formulations containing lower hormonal doses of estrogens and 
progestogens.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>8. CARBOHYDRATE AND LIPID METABOLIC EFFECTS<p>Oral contraceptives have been shown to cause <span class="product-label-link" type="condition" conceptid="44808385" conceptname="Pre-diabetes">glucose intolerance</span> 
in a significant percentage of users. Oral contraceptives containing greater 
than 75 micrograms of estrogens cause <span class="product-label-link" type="condition" conceptid="4307509" conceptname="Hyperinsulinism">hyperinsulinism</span>, while lower doses of 
estrogen cause less <span class="product-label-link" type="condition" conceptid="44808385" conceptname="Pre-diabetes">glucose intolerance</span>. Progestogens increase insulin secretion 
and create <span class="product-label-link" type="condition" conceptid="4168924" conceptname="Drug resistance to insulin">insulin resistance</span>, this effect varying with different progestational 
agents. However, in the nondiabetic woman, oral contraceptives appear to have no 
effect on fasting blood glucose. Because of these demonstrated effects, 
prediabetic and diabetic women should be carefully observed while taking oral 
contraceptives.</p>
<p>A small proportion of women will have persistent <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span> while 
on the pill. As discussed earlier (see <span class="Bold"><a href="#i4i_warnings_id_732d4fa2-5aa3-499f-9c15-613a3e67732a">WARNINGS</a></span><span class="Bold"><a href="#i4i_section_id_e787fc38-fed0-468f-bd92-72a5376666bf">1.a.</a></span> and 
<span class="Bold"><a href="#i4i_section_id_07d5f87c-cb3c-4a4e-8315-7616618a1bc0">1.d.</a></span>), 
changes in serum triglycerides and lipoprotein levels have been reported in oral 
contraceptive users.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>9. ELEVATED BLOOD PRESSURE<p>Women with significant <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> should not be started on 
hormonal contraceptives. An increase in blood pressure has been reported in 
women taking oral contraceptives, and this increase is more likely in older oral 
contraceptive users and with continued use. Data from the Royal College of 
General Practitioners and subsequent randomized trials have shown that the 
incidence of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> increases with increasing concentrations of 
progestogens.</p>
<p>Women with a history of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> or <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>-related diseases, or 
<span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> should be encouraged to use another method of contraception. If 
women elect to use oral contraceptives, they should be monitored closely and if 
significant elevation of blood pressure occurs, oral contraceptives should be 
discontinued (see <span class="Bold"><a href="#i4i_contraindications_id_27afe00c-b408-4fd7-b8a5-228c03e543a3">CONTRAINDICATIONS</a></span> 
section). For most women, elevated blood pressure will return to normal after 
stopping oral contraceptives, and there is no difference in the occurrence of 
<span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> among ever- and never-users.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>10. <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">HEADACHE</span><p>The onset or exacerbation of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> or development of <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> 
with a new pattern which is recurrent, persistent, or severe requires 
discontinuation of oral contraceptives and evaluation of the cause (see <span class="Bold"><a href="#i4i_warnings_id_732d4fa2-5aa3-499f-9c15-613a3e67732a">WARNINGS</a></span><span class="Bold"><a href="#i4i_section_id_d55ed777-c4b3-48fc-b039-ef81055b04dd">1.c.</a></span>).</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>11. <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">BLEEDING</span> IRREGULARITIES<p>Breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and spotting are sometimes encountered in 
patients on oral contraceptives, especially during the first three months of 
use. If <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> persists or recurs, nonhormonal causes should be considered and 
adequate diagnostic measures taken to rule out malignancy or pregnancy as in the 
case of any abnormal <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span>. If pathology has been excluded, time or a 
change to another formulation may solve the problem. </p>
<p>Absence of a withdrawal menses may also occur. In the event of <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span> for 
two cycles or more, pregnancy should be ruled out. In the clinical trial with 
Loestrin 24 Fe, 31-41% of the women using Loestrin 24 Fe did not have a 
withdrawal menses in at least one of 6 cycles of use. </p>
<p>Some women may experience post-pill <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span> or <span class="product-label-link" type="condition" conceptid="442274" conceptname="Oligomenorrhea">oligomenorrhea</span> (possibly 
with <span class="product-label-link" type="condition" conceptid="4144685" conceptname="Anovulation">anovulation</span>), especially when such a condition was preexistent.</p>
<br>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-9"></a><p></p>
<h1>PRECAUTIONS</h1>
<a href="http://"></a>1. <span class="product-label-link" type="condition" conceptid="440647" conceptname="Sexually transmitted infectious disease">SEXUALLY TRANSMITTED DISEASES</span> <p class="First"><span class="Bold">Patients should be counseled that this product 
does not protect against <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> (AIDS) and other sexually transmitted 
diseases.</span></p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>2. PHYSICAL EXAMINATION AND FOLLOW-UP<p>A periodic personal and family medical history and complete 
physical examination are appropriate for all women, including women using oral 
contraceptives. The physical examination, however, may be deferred until after 
initiation of oral contraceptives if requested by the woman and judged 
appropriate by the clinician. The physical examination should include special 
reference to blood pressure, breasts, abdomen and pelvic organs, including 
cervical <span class="product-label-link" type="condition" conceptid="45771295" conceptname="Cytology">cytology</span>, and relevant laboratory tests. In case of undiagnosed, 
persistent or recurrent abnormal <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span>, appropriate measures should 
be conducted to rule out malignancy. Women with a strong family history of 
breast cancer or who have breast <span class="product-label-link" type="condition" conceptid="4101098" conceptname="Nodule">nodules</span> should be monitored with particular 
care.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>3. LIPID DISORDERS<p>Women who are being treated for <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemias</span> should be 
followed closely if they elect to use oral contraceptives. Some progestogens may 
elevate LDL levels and may render the control of <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemias</span> more difficult. 
(See <span class="Bold"><a href="#i4i_warnings_id_732d4fa2-5aa3-499f-9c15-613a3e67732a">WARNINGS</a><a href="#i4i_section_id_07d5f87c-cb3c-4a4e-8315-7616618a1bc0">1.d</a>.</span>).</p>
<p>In patients with familial defects of lipoprotein metabolism receiving 
estrogen-containing preparations, there have been case reports of significant 
elevations of plasma triglycerides leading to <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>4. LIVER FUNCTION<p>If <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> develops in any woman receiving such drugs, the 
medication should be discontinued. Steroid hormones may be poorly metabolized in 
patients with <span class="product-label-link" type="condition" conceptid="4326594" conceptname="Abnormal liver function">impaired liver function</span>.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>5. <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">FLUID RETENTION</span><p>Oral contraceptives may cause some degree of <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>. 
They should be prescribed with caution, and only with careful monitoring, in 
patients with conditions which might be aggravated by <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>6. <span class="product-label-link" type="condition" conceptid="4305081" conceptname="Emotional problems">EMOTIONAL DISORDERS</span><p>Women with a history of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> should be carefully observed 
and the drug discontinued if <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> recurs to a serious degree. Patients 
becoming significantly depressed while taking oral contraceptives should stop 
the medication and use an alternate method of contraception in an attempt to 
determine whether the symptom is drug related. Women with a history of 
<span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> should be carefully observed and the drug discontinued if <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> 
recurs to a serious degree.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>7. CONTACT LENSES<p>Contact lens wearers who develop visual changes or changes in 
lens tolerance should be assessed by an ophthalmologist.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>8. DRUG INTERACTIONS<p><span class="Bold">Changes in contraceptive effectiveness 
associated with co-administration of other products:</span></p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a><span class="Bold">a. Anti-infective agents and 
anticonvulsants</span><p>Contraceptive effectiveness may be reduced when hormonal 
contraceptives are co-administered with antibiotics, anticonvulsants, and other 
drugs that increase the metabolism of contraceptive steroids. This could result 
in <span class="product-label-link" type="condition" conceptid="4307820" conceptname="Unplanned pregnancy">unintended pregnancy</span> or breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. Examples include rifampin, 
barbiturates, phenylbutazone, phenytoin, carbamazepine, felbamate, 
oxcarbazepine, topiramate, and griseofulvin. </p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a><span class="Bold">b. Anti-HIV protease 
inhibitors</span><p>Several of the anti-HIV protease inhibitors have been studied 
with co-administration of oral combination hormonal contraceptives; significant 
changes (increase and decrease) in the plasma levels of the estrogen and 
progestin have been noted in some cases. The safety and efficacy of combination 
oral contraceptive products may be affected with co-administration of anti-HIV 
protease inhibitors. Healthcare providers should refer to the label of the 
individual anti-HIV protease inhibitors for further drug-drug interaction 
information.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a><span class="Bold">c. Herbal products</span><p>Herbal products containing St. John’s Wort (hypericum perforatum) 
may induce hepatic enzymes (cytochrome P450) and p-glycoprotein transporter and 
may reduce the effectiveness of contraceptive steroids. This may also result in 
breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. </p>
<p><span class="Bold">Increase in plasma levels of estradiol associated with 
co-administered drugs:</span></p>
<p>Co-administration of atorvastatin and certain combination oral contraceptives 
containing ethinyl estradiol increase AUC values for ethinyl estradiol by 
approximately 20%. Ascorbic acid and acetaminophen may increase plasma ethinyl 
estradiol levels, possibly by inhibition of conjugation. CYP3A4 inhibitors such 
as itraconazole or ketoconazole may increase plasma hormone levels.</p>
<p><span class="Bold">Changes in plasma levels of co-administered drugs:</span></p>
<p>Combination hormonal contraceptives containing some synthetic estrogens 
(e.g., ethinyl estradiol) may inhibit the metabolism of other compounds. 
Increased plasma concentrations of cyclosporine, prednisolone, and theophylline 
have been reported with concomitant administration of combination oral 
contraceptives. Decreased plasma concentrations of acetaminophen and increased 
clearance of temazepam, salicylic acid, morphine and clofibric acid, due to 
induction of conjugation have been noted when these drugs were administered with 
combination oral contraceptives.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>9. INTERACTIONS WITH LABORATORY TESTS<p>Certain endocrine and liver function tests and blood components 
may be affected by oral contraceptives:</p>
<ol>
<li>Increased <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> and factors VII, VIII, IX, and X; decreased 
antithrombin 3; increased norepinephrine-induced platelet aggregability. 
</li>
<li>Increased thyroid-binding globulin (TBG) leading to increased circulating 
total thyroid hormone, as measured by protein-bound iodine (PBI), T<span class="Sub">4</span> by column or by radioimmunoassay. Free T<span class="Sub">3</span> resin uptake is decreased, reflecting the elevated TBG, free 
T<span class="Sub">4</span> concentration is unaltered. 
</li>
<li>Other binding proteins may be elevated in serum. 
</li>
<li><span class="product-label-link" type="condition" conceptid="4206320" conceptname="Sex steroid binding globulin">Sex hormone binding globulins</span> are increased and result in elevated levels of 
total circulating sex steroids and corticoids; however, free or biologically 
active levels remain unchanged. 
</li>
<li>Triglycerides may be increased and levels of various other lipids and 
lipoproteins may be affected. 
</li>
<li>Glucose tolerance may be decreased. 
</li>
<li>Serum folate levels may be depressed by oral contraceptive therapy. This may 
be of clinical significance if a woman becomes pregnant shortly after 
discontinuing oral contraceptives. </li>
</ol>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>10. CARCINOGENESIS <p>See <span class="Bold"><a href="#i4i_warnings_id_732d4fa2-5aa3-499f-9c15-613a3e67732a">WARNINGS 
</a></span>section.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>11. PREGNANCY <p>Pregnancy Category X. See <span class="Bold"><a href="#i4i_contraindications_id_27afe00c-b408-4fd7-b8a5-228c03e543a3">CONTRAINDICATIONS 
</a></span>and <span class="Bold"><a href="#i4i_warnings_id_732d4fa2-5aa3-499f-9c15-613a3e67732a">WARNINGS</a></span> 
sections.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>12. NURSING MOTHERS<p>Small amounts of oral contraceptive steroids and/or metabolites 
have been identified in the milk of nursing mothers and a few adverse effects on 
the child have been reported, including <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> and <span class="product-label-link" type="condition" conceptid="78474" conceptname="Hypertrophy of breast">breast enlargement</span>. In 
addition, combination oral contraceptives given in the postpartum period may 
interfere with lactation by decreasing the quantity and quality of breast milk. 
If possible, the nursing mother should be advised not to use combination oral 
contraceptives but to use other forms of contraception until she has completely 
weaned her child.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>13. PEDIATRIC USE <p>Safety and efficacy of Loestrin 24 Fe have been established in 
women of reproductive age. Safety and efficacy are expected to be the same in 
postpubertal adolescents under the age of 16 years and in users age 16 years and 
older. Use of this product before <span class="product-label-link" type="condition" conceptid="4061459" conceptname="Menarche">menarche</span> is not indicated.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>14. GERIATRIC USE<p>This product has not been studied in women over 65 years of age 
and is not indicated in this population.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-10"></a><p></p>
<h1>INFORMATION FOR THE PATIENT</h1>
<p class="First">See <a href="#i4i_patient_package_insert_id_c3c16dd9-42ba-472f-9bcf-2653ba298eaa">Patient 
Labeling </a>printed below.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-11"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">The most common adverse events reported by 2 - 6% of the 743 
women using Loestrin  24 Fe were the following, in order of decreasing 
incidence: <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="198363" conceptname="Candidiasis of vagina">vaginal candidiasis</span>, <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory infection</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, 
<span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">menstrual cramps</span>, <span class="product-label-link" type="condition" conceptid="4208409" conceptname="Breast tenderness">breast tenderness</span>, <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>, <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span> (bacterial), abnormal 
cervical smear, <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>, <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">mood swings</span>, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, 
<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="195012" conceptname="Intermenstrual bleeding - irregular">metrorrhagia</span>.</p>
<p>Among the 743 women using Loestrin 24 Fe, 46 women (6.2%) withdrew because of 
an adverse event. Adverse events occurring in 3 or more subjects leading to 
discontinuation of treatment were, in decreasing order: abnormal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> 
(0.9%), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (0.8%), <span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">menstrual cramps</span> (0.4%), <span class="product-label-link" type="condition" conceptid="141693" conceptname="Elevated blood-pressure reading without diagnosis of hypertension">increased blood pressure</span> (0.4%), 
and irregular <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> (0.4%).</p>
<p>An increased risk of the following serious adverse reactions has been 
associated with the use of oral contraceptives (see <span class="Bold"><a href="#i4i_warnings_id_732d4fa2-5aa3-499f-9c15-613a3e67732a">WARNINGS</a> </span>section):</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">Thrombophlebitis</span> 
</li>
<li>Arterial <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span> 
</li>
<li><span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Pulmonary embolism</span> 
</li>
<li><span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial infarction</span> 
</li>
<li><span class="product-label-link" type="condition" conceptid="376713" conceptname="Cerebral hemorrhage">Cerebral hemorrhage</span> 
</li>
<li><span class="product-label-link" type="condition" conceptid="441874" conceptname="Cerebral thrombosis">Cerebral thrombosis</span> 
</li>
<li><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> 
</li>
<li><span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">Gallbladder disease</span> 
</li>
<li><span class="product-label-link" type="condition" conceptid="4301500" conceptname="Liver cell adenoma">Hepatic adenomas</span> or benign <span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">liver tumors</span> </li>
</ul>
<p>There is evidence of an association between the following conditions and the 
use of oral contraceptives:</p>
<ul>
<li>Mesenteric <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> 
</li>
<li>Retinal <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> </li>
</ul>
<p>The following adverse reactions have been reported in patients receiving oral 
contraceptives and are believed to be drug related:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> 
</li>
<li><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> 
</li>
<li><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal symptoms</span> (such as <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">cramps</span> and <span class="product-label-link" type="condition" conceptid="442597" conceptname="Swollen abdomen">bloating</span>) 
</li>
<li>Breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> 
</li>
<li>Spotting 
</li>
<li>Change in menstrual flow 
</li>
<li><span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">Amenorrhea</span> 
</li>
<li>Temporary <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">infertility</span> after discontinuation of treatment 
</li>
<li><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span>/<span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> 
</li>
<li><span class="product-label-link" type="condition" conceptid="4264234" conceptname="Chloasma">Melasma</span>/<span class="product-label-link" type="condition" conceptid="4264234" conceptname="Chloasma">chloasma</span> which may persist 
</li>
<li>Breast changes: <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, enlargement, and secretion 
</li>
<li>Change in weight or appetite (increase or decrease) 
</li>
<li>Change in cervical <span class="product-label-link" type="condition" conceptid="376132" conceptname="Ectropion">ectropion</span> and secretion 
</li>
<li>Possible diminution in lactation when given immediately postpartum 
</li>
<li><span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">Cholestatic jaundice</span> 
</li>
<li><span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine headache</span> 
</li>
<li><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> (allergic) 
</li>
<li><span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">Mood changes</span>, including <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> 
</li>
<li><span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">Vaginitis</span>, including <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">candidiasis</span> 
</li>
<li>Change in corneal curvature (steepening) 
</li>
<li>Intolerance to contact lenses 
</li>
<li>Decrease in serum folate levels 
</li>
<li>Exacerbation of <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span> 
</li>
<li>Exacerbation of <span class="product-label-link" type="condition" conceptid="4305376" conceptname="Porphyria">porphyria</span> 
</li>
<li>Exacerbation of <span class="product-label-link" type="condition" conceptid="440990" conceptname="Chorea">chorea</span> 
</li>
<li>Aggravation of <span class="product-label-link" type="condition" conceptid="312349" conceptname="Venous varices">varicose veins</span> 
</li>
<li>Anaphylactic/<span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span>, including <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, and 
severe reactions with respiratory and circulatory symptoms </li>
</ul>
<p>The following adverse reactions have been reported in users of oral 
contraceptives, and a causal association has been neither confirmed nor 
refuted:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">Acne</span> 
</li>
<li>Budd-Chiari syndrome 
</li>
<li><span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">Cataracts</span> 
</li>
<li><span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">Colitis</span> 
</li>
<li>Changes in libido 
</li>
<li><span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">Cystitis</span>-like syndrome 
</li>
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> 
</li>
<li><span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">Dysmenorrhea</span> 
</li>
<li><span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">Erythema multiforme</span> 
</li>
<li><span class="product-label-link" type="condition" conceptid="140176" conceptname="Erythema nodosum">Erythema nodosum</span> 
</li>
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> 
</li>
<li>Hemorrhagic <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">eruption</span> 
</li>
<li><span class="product-label-link" type="condition" conceptid="197253" conceptname="Hemolytic uremic syndrome">Hemolytic uremic syndrome</span> 
</li>
<li><span class="product-label-link" type="condition" conceptid="134718" conceptname="Hirsutism">Hirsutism</span> 
</li>
<li><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired renal function</span> 
</li>
<li>Loss of scalp hair 
</li>
<li><span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">Nervousness</span> 
</li>
<li><span class="product-label-link" type="condition" conceptid="374954" conceptname="Optic neuritis">Optic neuritis</span>, which may lead to partial or complete <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span> 
</li>
<li><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span> 
</li>
<li><span class="product-label-link" type="condition" conceptid="439081" conceptname="Premenstrual tension syndrome">Premenstrual syndrome</span> </li>
</ul>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-12"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Serious ill effects have not been reported following acute ingestion of large 
doses of oral contraceptives by young children. Overdosage may cause <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and 
<span class="product-label-link" type="condition" conceptid="4161407" conceptname="Withdrawal bleeding">withdrawal bleeding</span> may occur in females.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13"></a><p></p>
<h1>NONCONTRACEPTIVE HEALTH BENEFITS</h1>
<p class="First">The following noncontraceptive health benefits related to the use 
of oral contraceptives are supported by epidemiological studies which largely 
utilized oral-contraceptive formulations containing doses exceeding 0.035 mg of 
ethinyl estradiol or 0.05 mg of mestranol.</p>
<p>Effects on menses:</p>
<ul>
<li>Increased menstrual cycle regularity 
</li>
<li>Decreased blood loss and decreased incidence of iron-<span class="product-label-link" type="condition" conceptid="4280354" conceptname="Nutritional anemia">deficiency anemia</span> 
</li>
<li>Decreased incidence of <span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">dysmenorrhea</span> </li>
</ul>
<p>Effects related to inhibition of ovulation:</p>
<ul>
<li>Decreased incidence of functional <span class="product-label-link" type="condition" conceptid="193530" conceptname="Follicular cyst of ovary">ovarian cysts</span> 
</li>
<li>Decreased incidence of ectopic pregnancies </li>
</ul>
<p>Effects from long-term use:</p>
<ul>
<li>Decreased incidence of fibroadenomas and fibrocystic disease of the breast 
</li>
<li>Decreased incidence of acute <span class="product-label-link" type="condition" conceptid="199067" conceptname="Inflammatory disease of female pelvic organs AND/OR tissues">pelvic inflammatory disease</span> 
</li>
<li>Decreased incidence of endometrial cancer 
</li>
<li>Decreased incidence of ovarian cancer </li>
</ul>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-14"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">To achieve maximum contraceptive effectiveness, Loestrin 24 Fe 
should be taken exactly as directed and at intervals not exceeding 24 hours. 
Loestrin 24 Fe tablets may be administered without regard to meals. </p>
<p>Loestrin 24 Fe provides a regimen consisting of 24 white active tablets of 
Loestrin 24 Fe and 4 brown non-hormonal (placebo) tablets of ferrous fumarate. 
The ferrous fumarate tablets do not serve any therapeutic purpose. </p>
<p><span class="Bold">During the first cycle of use:</span></p>
<p>The possibility of ovulation and conception prior to initiation of medication 
should be considered. The patient is instructed to begin taking Loestrin 24 Fe  
on either Day 1 of menstruation (Day 1 Start) or the first Sunday after the 
onset of menstruation (Sunday Start). If menstruation begins on a Sunday, the 
first tablet (white) is taken that day. One white tablet should be taken daily 
for 24 consecutive days followed by one brown tablet daily for 4 consecutive 
days. <span class="product-label-link" type="condition" conceptid="4161407" conceptname="Withdrawal bleeding">Withdrawal bleeding</span> should usually occur within three days following 
discontinuation of white tablets and may not have finished before the next pack 
is started. During the first cycle with a Sunday start, contraceptive reliance 
should not be placed on Loestrin 24 Fe until a white tablet has been taken daily 
for 7 consecutive days and a non-hormonal back-up method of birth control (such 
as condoms or spermicide) should be used during those 7 days. </p>
<p>The patient begins her next and all subsequent 28-day courses of tablets on 
the same day of the week on which she began her first course, following the same 
schedule: 24 days on white tablets—4 days on brown tablets. If in any cycle the 
patient starts tablets later than the proper day, she should protect herself 
against pregnancy by using a non-hormonal back-up method of birth control until 
she has taken a white tablet daily for 7 consecutive days.</p>
<p><span class="Bold">Switching from another hormonal method of 
contraception:</span></p>
<p>When the patient is switching to Loestrin 24 Fe after completing a 21-day 
regimen of oral contraceptive tablets, transdermal patches, or a vaginal ring, 
she should wait 7 days after her last tablet, patch, or ring before she starts 
Loestrin 24 Fe. She will probably experience <span class="product-label-link" type="condition" conceptid="4161407" conceptname="Withdrawal bleeding">withdrawal bleeding</span> during that 
week. She should be sure that no more than 7 days pass after her previous 21-day 
regimen. When the patient is switching to Loestrin 24 Fe after completing a 
28-day regimen of oral contraceptive tablets, she should start her first pack of 
Loestrin 24 Fe on the day after her last tablet. She should not wait any days 
between packs. The patient may switch any day from a progestin-only pill and 
should begin Loestrin 24 Fe the next day. If switching from an implant or 
injection, the patient should start Loestrin 24 Fe on the day of implant removal 
or, if using an injection, the day the next injection would be due. </p>
<p><span class="Bold">If spotting or breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> occurs:</span></p>
<p>The patient is instructed to continue on the same regimen. This type of 
<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> is usually transient and without significance; however, if the <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> 
is persistent or prolonged, the patient is advised to consult her healthcare 
provider. Although pregnancy is unlikely if Loestrin 24 Fe is taken according to 
directions, if <span class="product-label-link" type="condition" conceptid="4161407" conceptname="Withdrawal bleeding">withdrawal bleeding</span> does not occur, the possibility of pregnancy 
must be considered. If the patient has not adhered to the prescribed schedule 
(missed one or more tablets or started taking them on a day later than she 
should have), the probability of pregnancy should be considered at the time of 
the first missed period and appropriate diagnostic measures taken. If the 
patient has adhered to the prescribed regimen and misses two consecutive 
periods, pregnancy should be ruled out. Hormonal contraceptives should be 
discontinued if pregnancy is confirmed.</p>
<p><span class="Bold">For additional patient instructions regarding missed 
pills:</span></p>
<p>See the “WHAT TO DO IF YOU MISS PILLS? section in the <span class="Bold"><a href="#i4i_patient_package_insert_id_bda062e8-268b-43a4-ad97-96aa2c0833b5">DETAILED 
PATIENT LABELING</a></span>. Any time the patient misses two or more white 
tablets, she should also use another method of non-hormonal back-up 
contraception until she has taken a white tablet daily for seven consecutive 
days. If the patient misses one or more brown tablets, she is still protected 
against pregnancy <span class="Bold">provided</span> she begins taking the active 
white tablets again on the proper day. If breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> occurs following 
missed white tablets, it will usually be transient and of no consequence. The 
possibility of ovulation increases with each successive day that scheduled white 
tablets are missed. Therefore, the risk of pregnancy increases with each active 
(white) tablet missed.</p>
<p><span class="Bold">Use after pregnancy, abortion or <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">miscarriage</span>:</span></p>
<p>Loestrin 24 Fe should be initiated no earlier than 28 days postpartum in the 
nonlactating mother due to the increased risk for <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span>. When the 
tablets are administered in the postpartum period, the increased risk of 
thromboembolic disease associated with the postpartum period must be considered 
(see <span class="Bold"><a href="#i4i_contraindications_id_27afe00c-b408-4fd7-b8a5-228c03e543a3">CONTRAINDICATIONS</a></span>, 
<span class="Bold"><a href="#i4i_warnings_id_732d4fa2-5aa3-499f-9c15-613a3e67732a">WARNINGS</a></span>, 
and <span class="Bold"><a href="#i4i_precautions_id_c75261cb-c63c-4934-9a56-d433e20e780a">PRECAUTIONS</a></span> 
concerning thromboembolic disease). The patient should be advised to use a 
non-hormonal back-up method for the first 7 days of tablet taking. However, if 
intercourse has already occurred, the possibility of ovulation and conception 
prior to initiation of medication should be considered. </p>
<p>Loestrin 24 Fe may be initiated after a first-trimester abortion or 
<span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">miscarriage</span>; if the patient starts Loestrin 24 Fe immediately, additional 
contraceptive measures are not needed. </p>
<p>For additional patient instructions regarding complete dosing instructions, 
see the “HOW TO TAKE THE PILL? section in the <span class="Bold"><a href="#i4i_patient_package_insert_id_bda062e8-268b-43a4-ad97-96aa2c0833b5">DETAILED 
PATIENT LABELING</a></span>.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-15"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Loestrin<span class="Sup">®</span> 24 Fe is available in <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> 
cards (dispensers) containing 24 white active tablets and 4 brown placebo 
tablets. Each white, round tablet contains 1 mg of norethindrone acetate and 20 
mcg of ethinyl estradiol and is imprinted with WC on one side and 530 on the 
other. Each brown, round tablet contains 75 mg ferrous fumarate.</p>
<p>NDC 54868-6100-0 - <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> cards<br></p>
<p><span class="Bold">Rx only</span></p>
<a href="#section-"></a><a href="#section-"></a><p>Keep this drug and all drugs out of the reach of 
children.<br>Store at 25° C (77° F); excursions permitted to 15 - 30° C (59 - 
86° F) [see USP Controlled Room Temperature].</p>
<p>References are available upon request.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-16"></a><p></p>
<h1>PATIENT BRIEF SUMMARY</h1>
<p class="First"><span class="Bold">This product (like all oral contraceptives) is 
intended to prevent pregnancy. It does not protect against <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> (AIDS) 
and other <span class="product-label-link" type="condition" conceptid="440647" conceptname="Sexually transmitted infectious disease">sexually transmitted diseases</span>.</span></p>
<p>Oral contraceptives, also known as "birth control pills" or "the pill", are 
taken to prevent pregnancy, and when taken correctly without missing any pills, 
have a failure rate of about 1% per year (1 pregnancy per 100 women per year of 
use). The typical failure rate of pill users is 5% (5 pregnancies per 100 women 
per year of use) when women who miss pills are included.</p>
<p>For the majority of women, oral contraceptives can be taken safely. But for 
some women oral contraceptive use is associated with certain serious medical 
problems that can be life-threatening or may cause temporary or permanent 
<span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span> or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. The risks associated with taking oral contraceptives 
increase significantly if you:</p>
<ul>
<li>Smoke 
</li>
<li>Have high blood pressure, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, high <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, or are obese 
</li>
<li>Have or have had <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">clotting disorders</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span> 
(severe <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pains</span>), cancer of the breast or sex organs, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, or malignant 
or benign <span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">liver tumors</span> </li>
</ul>
<p>You should not take the pill if you are pregnant or have unexplained vaginal 
<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.</p>
<p>Although cardiovascular disease risks may be increased with oral 
contraceptive use after age 40 in healthy, non-smoking women (even with the 
newer low-dose formulations), there are also greater potential health risks 
associated with pregnancy in older women.</p>
<a href="http://"></a><a name="ie9a5cf76-6c0a-4821-894b-cbf87a59a81d"></a><table width="0.000">
<col>
<col>
<tbody class="Headless"><tr class="First Last"><td><span class="Bold">Cigarette smoking increases the risk of serious adverse effects on 
the heart and blood vessels from oral contraceptive use. This risk increases 
with age and with the amount of smoking (15 or more cigarettes per day has been 
associated with a significantly increased risk) and is quite marked in women 
over 35 years of age. Women who use oral contraceptives should not 
smoke.</span></td></tr></tbody>
</table>
<p>Most side effects of the pill are not serious. The most common are <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, 
<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or spotting between menstrual periods, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, breast 
<span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, and difficulty wearing contact lenses. These side effects, 
especially <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, may decrease or subside within the first three 
months of use.</p>
<p>The serious side effects of the pill occur very infrequently, especially if 
you are in good health and do not smoke. However, you should know that the 
following medical conditions have been associated with or made worse by the 
pill:</p>
<p>1. Blood clots in the legs (<span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>), lungs (<span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>), 
stoppage or rupture of a blood vessel in the brain (<span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>), blockage of blood 
vessels in the heart (<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> or <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>), or other organs of the 
body. As mentioned above, smoking increases the risk of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attacks</span> and 
<span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span> and subsequent serious medical consequences. Women with <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> 
<span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> also may be at increased risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> when taking the pill. </p>
<p>2. <span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">Liver tumors</span>, which may rupture and cause severe <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. A possible but 
not definite association has been found with the pill and liver cancer. However, 
liver cancers are extremely rare. The chance of developing liver cancer from 
using the pill is thus even rarer.</p>
<p>3. High blood pressure, although blood pressure usually returns to normal 
when the pill is stopped.</p>
<p>The symptoms associated with these serious side effects are discussed in the 
<span class="Bold">DETAILED PATIENT INFORMATION</span> leaflet given to you with 
your supply of pills. Notify your healthcare provider if you notice any unusual 
physical disturbances while taking the pill. In addition, drugs such as 
rifampin, as well as some anticonvulsants and some antibiotics, and herbal 
preparations containing St. John's Wort (hypericum perforatum), may decrease 
oral contraceptive effectiveness.</p>
<p>Breast cancer has been diagnosed slightly more often in women who use the 
pill than in women of the same age who do not use the pill. This very small 
increase in the number of breast cancer diagnoses gradually disappears during 
the 10 years after stopping use of the pill. It is not known whether the 
difference is caused by the pill. It may be that women taking the pill are 
examined more often, so that breast cancer is more likely to be detected. You 
should have regular breast examinations by a healthcare provider and examine 
your own breasts monthly. Tell your healthcare provider if you have a family 
history of breast cancer or if you have had breast <span class="product-label-link" type="condition" conceptid="4101098" conceptname="Nodule">nodules</span> or an abnormal 
mammogram. Women who currently have or have had breast cancer should not use 
hormonal contraceptives because breast cancer is usually a hormone-sensitive 
tumor.</p>
<p>Some studies have found an increase in the incidence of cancer or 
precancerous lesions of the cervix in women who use the pill. However, this 
finding may be related to factors other than the use of the pill.</p>
<p>Taking the combination pill provides some important noncontraceptive health 
benefits. These include less painful menstruation, less menstrual blood loss and 
<span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, fewer <span class="product-label-link" type="condition" conceptid="4003306" conceptname="Infection of pelvis">pelvic infections</span>, and fewer cancers of the ovary and the lining 
of the uterus.</p>
<p>Be sure to discuss any medical condition you may have with your healthcare 
provider. Your healthcare provider will take a medical and family history before 
prescribing oral contraceptives and will examine you. The physical examination 
may be delayed to another time if you request it and the healthcare provider 
believes that it is a good medical practice to postpone it. You should be 
reexamined at least once a year while taking oral contraceptives. The DETAILED 
PATIENT INFORMATION leaflet gives you further information which you should read 
and discuss with your healthcare provider.</p>
<p><span class="Bold">DOSAGE AND ADMINISTRATION </span></p>
<p><span class="Bold">HOW TO TAKE Loestrin 24</span><span class="Bold"> Fe</span></p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a><p><span class="Bold">IMPORTANT POINTS TO REMEMBER</span></p>
<a href="http://"></a><a href="http://"></a><p><span class="Bold"><span class="Italics">BEFORE</span> YOU START 
TAKING YOUR PILLS:</span></p>
<ol>
<li>BE SURE TO READ THESE DIRECTIONS: 
<ul>
<li>Before you start taking your pills 
</li>
<li>Anytime you are not sure what to do </li>
</ul>
</li>
<li>TAKE ONE PILL EVERY DAY AT THE SAME TIME. <br>If you miss pills you could 
get pregnant. This includes starting the pack late. The more pills you miss, the 
more likely you are to get pregnant. 
</li>
<li>MANY WOMEN HAVE SPOTTING OR LIGHT <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">BLEEDING</span>, OR MAY FEEL SICK TO THEIR 
STOMACH WHILE TAKING THE FIRST 1 to 3 PACKS OF PILLS.<br>If you have spotting or 
light <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or feel sick to your stomach, do not stop taking the pill. The 
problem will usually go away. If it doesn't go away, check with your healthcare 
provider. 
</li>
<li>MISSING PILLS CAN ALSO CAUSE SPOTTING OR LIGHT <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">BLEEDING</span>, even if you take 
these missed pills. On the days you take 2 pills to make up for missed pills, 
you could also feel a little sick to your stomach. 
</li>
<li>IF YOU HAVE <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">VOMITING</span> (within 3 to 4 hours after you take your pill), you 
should follow the instructions for WHAT TO DO IF YOU MISS PILLS. IF YOU HAVE 
<span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">DIARRHEA</span> or IF YOU TAKE CERTAIN MEDICINES, including some antibiotics, or the 
herbal supplement St. John’s Wort, your pills may not work as well. Use a 
back-up method of birth control (such as condoms or spermicide) until you check 
with your healthcare provider. 
</li>
<li>IF YOU HAVE TROUBLE REMEMBERING TO TAKE THE PILL, talk to your healthcare 
provider about how to make pill-taking easier or about using another method of 
birth control. 
</li>
<li>IF YOU HAVE ANY QUESTIONS OR ARE UNSURE ABOUT THE INFORMATION IN THIS 
LEAFLET, call your healthcare provider. </li>
</ol>
<a href="http://"></a><a href="http://"></a><a href="http://"></a><p><span class="Bold"><span class="Italics">BEFORE  </span>YOU START 
TAKING YOUR PILLS</span></p>
<a href="http://"></a><a href="http://"></a><p>1. DECIDE WHAT TIME OF DAY YOU WANT TO TAKE YOUR PILL.<br>It is 
important to take it at about the same time every day.</p>2. LOOK AT YOUR PILL PACK: <br><p>Loestrin 24 Fe contains 24 "active" WHITE 
PILLS (with hormones) for WEEKS 1, 2, 3 and the first part of WEEK 4, and 4 
"reminder" BROWN PILLS (without hormones) for the last part of WEEK 4.<img alt="image of pill pack" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4cafa90a-9903-40d0-b8be-6ad78018b4b6&amp;name=pill%20pack.jpg"></p>
<p>3. ALSO FIND:</p>
<ul>
<li>where on the pack to start taking pills, 
</li>
<li>in what order to take the pills (follow the arrows), and 
</li>
<li>the week numbers as shown in the picture above. </li>
</ul>
<p>4. BE SURE YOU HAVE READY AT ALL TIMES: </p>
<ul>
<li>ANOTHER KIND OF BIRTH CONTROL (such as condoms or spermicide) to use as a 
back-up in case you miss pills. 
</li>
<li>AN EXTRA, PILL PACK. </li>
</ul>
<a href="http://"></a><a href="http://"></a><a href="http://"></a><p><span class="Bold">WHEN TO START THE <span class="Italics">FIRST</span> PACK OF PILLS</span></p>
<a href="http://"></a><a href="http://"></a><p>You have a choice of which day to start taking your first pack of 
pills. Decide with your healthcare provider which is the best day for you. Pick 
a time of day that will be easy to remember.</p>
<p>DAY-1 START:</p>
<ol>
<li>Pick the day label strip that starts with the first day of your period. 
(This is the day you start <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or spotting, even if it is almost midnight 
when the <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> begins.) 
</li>
<li>Place this day label strip on the tablet dispenser over the area that has 
the days of the week (starting with Sunday) printed on the plastic. 
</li>
<li>Take the first white pill of the first pack during the first 24 hours of 
your period. 
</li>
<li>You will not need to use a back-up method of birth control, since you are 
starting the pill at the beginning of your period. </li>
</ol>
<p>SUNDAY START:</p>
<ol>
<li>Take the first white pill of the first pack on the Sunday after your period 
starts, even if you are still <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. If your period begins on Sunday, start 
the pack that same day. 
</li>
<li>Use another method of birth control as a back-up method if you have sex 
anytime from the Sunday you start your first pack until the next Sunday (7 
days). Condoms or spermicide are good back-up methods of birth control. 
</li>
</ol>
<p>WHEN YOU SWITCH FROM A DIFFERENT METHOD OF HORMONAL CONTRACEPTION</p>
<ul>
<li>If your previous method had 28 pills, finish taking all 28 pills, then start 
taking Loestrin 24 Fe  on the day after the last pill. 
</li>
<li>If your previous method had 21 pills, finish taking all 21 pills, and wait 7 
days before starting Loestrin 24 Fe<span class="Bold">. </span>
</li>
<li>When you switch from a vaginal ring or skin patch, finish the 21 days of 
use, and wait 7 days after removal of the ring or patch before starting Loestrin 
24 Fe. 
</li>
<li>When you switch from a progestin-only pill, you should start Loestrin 24 Fe 
the next day. 
</li>
<li>When you switch from an implant or injectable contraceptive, you should 
start Loestrin 24 Fe on the day of implant removal or, if using an injectable 
contraceptive, the day on which the next injection would be due. </li>
</ul>
<a href="http://"></a><a href="http://"></a><a href="http://"></a><p><span class="Bold">WHAT TO DO DURING THE MONTH</span></p>
<a href="http://"></a><a href="http://"></a><ol>
<li>TAKE ONE PILL AT THE SAME TIME EVERY DAY UNTIL THE PACK IS EMPTY. Do not 
skip pills even if you are spotting or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> between monthly periods or feel 
sick to your stomach (<span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>). Do not skip pills even if you do not have sex 
very often. 
</li>
<li>WHEN YOU FINISH A PACK OF YOUR Loestrin 24 Fe: Start the next pack on the 
day after your last brown “reminder" pill. Do not wait any days between packs. 
</li>
</ol>
<a href="http://"></a><a href="http://"></a><a href="http://"></a><p><span class="Bold">WHAT TO DO IF YOU MISS PILLS</span></p>
<a href="http://"></a><a href="http://"></a><p>Birth control pills may not be as effective if you miss any white 
pills, and particularly if you miss the first few or the last few white pills in 
a pack.</p>
<p><span class="Bold">If you MISS 1 white pill:</span></p>
<ol>
<li>Take it as soon as you remember. Take the next pill at your regular time. 
This means you may take 2 pills in 1 day. 
</li>
<li>You do not need to use a back-up birth control method if you have sex. 
</li>
</ol>
<p><span class="Bold">If you MISS 2 white pills in a row in WEEK 1 OR WEEK 2 of 
your pack:</span></p>
<ol>
<li>Take 2 pills on the day you remember and 2 pills the next day. 
</li>
<li>Then take 1 pill a day until you finish the pack. 
</li>
<li>You COULD BECOME PREGNANT if you have sex during the <span class="Italics">7 
days</span> after you restart your pills. You MUST use a non-hormonal birth 
control method (such as condoms or spermicide) as a back-up for those 7 days. 
</li>
</ol>
<p><span class="Bold">If you MISS 2 white pills in a row in WEEK 3 or WEEK 4 of 
your pack:</span></p>
<ol>
<li>
<span class="Bold">1.If you are a Day 1 Starter</span>:<br>THROW OUT the rest 
of the pill pack and start a new pack that same day. <span class="Bold"><br>If you 
are a Sunday Starter</span>: <br>Keep taking 1 pill every day until 
Sunday.<br>On Sunday, THROW OUT the rest of the pack and start a new pack of 
pills that same day. 
</li>
<li>You may not have your period this month but this is expected. However, if 
you miss your period 2 months in a row, call your healthcare provider because 
you might be pregnant. 
</li>
<li>You COULD BECOME PREGNANT if you have sex during the <span class="Italics">7 
days</span> after you restart your pills. You MUST use a non-hormonal birth 
control method (such as condoms or spermicide) as a back-up for those 7 days 
after you restart your pills. </li>
</ol>
<p><span class="Bold">If you MISS 3 OR MORE white pills in a row at any 
time:</span></p>
<ol>
<li>
<span class="Bold">If you are a Day 1 Starter</span>:<br>THROW OUT the rest of 
the pill pack and start a new pack that same day. <span class="Bold"><br>If you 
are a Sunday Starter</span>:<br>Keep taking 1 pill every day until Sunday. 
<br>On Sunday, THROW OUT the rest of the pack and start a new pack of pills that 
same day. 
</li>
<li>You may not have your period this month but this is expected. However, if 
you miss your period 2 months in a row, call your healthcare provider because 
you might be pregnant. 
</li>
<li>You COULD BECOME PREGNANT if you have sex on the days when you missed pills 
or during the first <span class="Italics">7 days</span> after restarting your 
pills. You MUST use a non-hormonal birth control method (such as condoms or 
spermicide) as a back-up the next time you have sex and for the first 7 days 
after you restart your pills. </li>
</ol>
<p><span class="Bold">If you forget any of the 4 brown "reminder" pills in Week 
4:</span></p>
<ol>
<li>THROW AWAY the pills you missed. 
</li>
<li>Keep taking 1 pill each day until the pack is empty. 
</li>
<li>You do not need to use a back-up method of birth control. </li>
</ol>
<p><span class="Bold">FINALLY, IF YOU ARE STILL NOT SURE WHAT TO DO ABOUT THE 
PILLS YOU HAVE MISSED: </span></p>
<ol>
<li>Use a BACK-UP METHOD of birth control anytime you have sex. 
</li>
<li>KEEP TAKING ONE WHITE PILL EACH DAY until you can reach your healthcare 
provider.</li>
</ol>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-17"></a><p></p>
<a href="http://"></a>DETAILED PATIENT PACKAGE INSERT<p class="First"><span class="Bold">This product (like all oral contraceptives) is 
intended to prevent pregnancy. It does not protect against <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> (AIDS) 
and other <span class="product-label-link" type="condition" conceptid="440647" conceptname="Sexually transmitted infectious disease">sexually transmitted diseases</span>.</span></p>
<p><span class="Bold">INTRODUCTION</span></p>
<p>Any woman who considers using oral contraceptives (the “birth control pill? 
or “the pill?) should understand the benefits and risks of using this form of 
birth control.</p>
<p>Although oral contraceptives have important advantages over other methods of 
contraception, they have certain risks that no other method has, and some of 
these risks may continue after you have stopped using the oral contraceptive. 
This leaflet will give you much of the information you will need to make this 
decision and will also help you determine if you are at risk of developing any 
of the serious side effects of the pill. It will tell you how to use Loestrin 24 
Fe properly so that it will be as effective as possible. However, this booklet 
is not a replacement for a careful discussion between you and your healthcare 
provider. You should discuss the information provided in this booklet with your 
healthcare provider, both when you first start taking the pill and during your 
revisits. You should also follow your healthcare provider’s advice with regard 
to regular check-ups while you are on Loestrin 24 Fe.</p>
<p><span class="Bold">EFFECTIVENESS OF ORAL CONTRACEPTIVES</span></p>
<p>Oral contraceptives or “birth control pill? or “the pill? are used to prevent 
pregnancy and are more effective than most other nonsurgical methods of birth 
control. The chance of becoming pregnant is approximately 1% per year (1 
pregnancy per 100 women per year of use) when the pills are taken correctly, and 
no pills are missed. Typical failure rates are 5% per year when women who miss 
pills are included. The chance of becoming pregnant increases with each missed 
"active" hormonal pill during a 28-day cycle.</p>
<p>In comparison, typical failure rates for other methods of birth control 
during the first year of use are as follows:</p>
<p>No birth control methods: 85%<br>Vaginal sponge: 20 to 40%<br>Cervical cap: 
20 to 40%<br>Spermicides alone: 26%<br>Periodic abstinence: 25%<br>Condom 
(female): 21%<br>Diaphragm with spermicides: 20%<br>Withdrawal: 19%<br>Condom 
(male): 14%<br>Female sterilization: less than 1% <br>IUD: less than 
1-2%<br>Injectable progestogen: less than 1%<br>Male sterilization: less than 
1%<br>Norplant<span class="Sup">®</span> system: less than 1%</p>
<p><span class="Bold">WHO SHOULD NOT TAKE ORAL CONTRACEPTIVES</span></p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a><p><span class="Bold">Cigarette smoking increases the risk of serious 
adverse effects on the heart and blood vessels from oral contraceptive use. This 
risk increases with age and with the amount of smoking (15 or more cigarettes 
per day has been associated with a significantly increased risk) and is quite 
marked in women over 35 years of age. Women who use oral contraceptives should 
not smoke.</span></p>
<a href="http://"></a><a href="http://"></a><p>Some women should not use the pill. You should not use the pill 
if you have or have ever had any of the following conditions:</p>
<ul>
<li>A history of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> 
</li>
<li>A history of blood clots in the legs (<span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>), lungs (pulmonary 
<span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">embolism</span>), or eyes 
</li>
<li>A history of blood clots in the deep veins of your legs 
</li>
<li><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span> (<span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>) 
</li>
<li>Known or suspected breast cancer or cancer of the lining of the uterus, 
cervix, vagina, or certain hormonally-sensitive cancers 
</li>
<li>Unexplained <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> (until a diagnosis is reached by your 
healthcare provider) 
</li>
<li>Yellowing of the whites of the eyes or of the skin (<span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>) during 
pregnancy or during previous use of hormonal contraceptives of any type (the 
pill, patch, vaginal ring, injection, or implant) 
</li>
<li><span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">Liver tumor</span> (benign or cancerous) 
</li>
<li>Known or suspected pregnancy 
</li>
<li>Heart valve or heart rhythm disorders that may be associated with formation 
of blood clots 
</li>
<li><span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> with complications of the kidneys, eyes, nerves, or blood vessels 
</li>
<li>Severe high blood pressure 
</li>
<li>Active liver disease with <span class="product-label-link" type="condition" conceptid="438878" conceptname="Liver function tests abnormal">abnormal liver function tests</span> 
</li>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergy</span> or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any of the components of Loestrin 24 Fe 
</li>
<li>A need for surgery with prolonged bedrest 
</li>
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headaches</span> with neurological symptoms </li>
</ul>
<p>Tell your healthcare provider if you have any of the above conditions. Your 
healthcare provider can recommend a safer method of birth control.</p>
<p><span class="Bold">OTHER CONSIDERATIONS BEFORE TAKING ORAL CONTRACEPTIVES 
</span></p>
<p>Tell your healthcare provider if you have or ever have had:</p>
<ul>
<li>Breast <span class="product-label-link" type="condition" conceptid="4101098" conceptname="Nodule">nodules</span>, fibrocystic disease of the breast or an abnormal breast 
x-ray or mammogram 
</li>
<li><span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> 
</li>
<li>Elevated <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> or triglycerides 
</li>
<li>High blood pressure 
</li>
<li><span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span> or other <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> or <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> 
</li>
<li><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> 
</li>
<li>Gallbladder, liver, heart, or kidney disease 
</li>
<li>Scanty or irregular menstrual periods </li>
</ul>
<p>Women with any of these conditions should be checked often by their 
healthcare provider if they choose to use oral contraceptives.</p>
<p>Talk to your healthcare provider about using Loestrin 24 Fe if you:</p>
<ul>
<li>Smoke 
</li>
<li>Recently had a baby 
</li>
<li>Recently had a <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">miscarriage</span> or abortion 
</li>
<li>Are breastfeeding 
</li>
<li>Are taking any other medications </li>
</ul>
<p><span class="Bold">RISKS OF TAKING ORAL CONTRACEPTIVES </span></p>
<p><span class="Bold">1. Risk of developing blood clots</span></p>
<p>Blood clots and blockage of blood vessels are the most serious side effects 
of taking oral contraceptives and can cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> or serious <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span>. In 
particular, a clot in the legs can cause <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>, and a clot that 
travels to the lungs can cause a sudden blocking of the vessel carrying blood to 
the lungs. Either of these can cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> or <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span>. Rarely, clots occur in 
the blood vessels of the eye and may cause <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">blindness</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">double vision</span>, or impaired 
vision.</p>
<p>If you take oral contraceptives and need elective surgery, need to stay in 
bed for a prolonged illness or injury, or have recently delivered a baby, you 
may be at risk of developing blood clots. You should consult your healthcare 
provider about stopping oral contraceptives four weeks before surgery and not 
taking oral contraceptives for two weeks after surgery or during bed rest. You 
should also not take oral contraceptives soon after delivery of a baby. It is 
advisable to wait for at least four weeks after delivery if you are not 
breastfeeding. If you are breastfeeding, you should wait until you have weaned 
your child before using the pill (see the section on <span class="Bold">breastfeeding</span> in <span class="Bold">GENERAL 
PRECAUTIONS</span>).</p>
<p>The risk of circulatory disease in oral contraceptive users may be higher in 
users of high-dose pills (containing 50 micrograms or higher of ethinyl 
estradiol) and may be greater with longer duration of oral contraceptive use. In 
addition, some of these increased risks may continue for a number of years after 
stopping oral contraceptives. The risk of abnormal blood clotting increases with 
age in both users and nonusers of oral contraceptives, but the increased risk 
from the oral contraceptive appears to be present at all ages. For women aged 20 
to 44 it is estimated that about 1 in 2,000 using oral contraceptives will be 
hospitalized each year because of abnormal clotting. Among nonusers in the same 
age group, about 1 in 20,000 would be hospitalized each year. For oral 
contraceptive users in general, it has been estimated that in women between the 
ages of 15 and 34 the risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> due to a circulatory disorder is about 1 in 
12,000 per year, whereas for nonusers the rate is about 1 in 50,000 per year. In 
the age group 35 to 44, the risk is estimated to be about 1 in 2,500 per year 
for oral contraceptive users and about 1 in 10,000 per year for nonusers.</p>
<p><span class="Bold">2. <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Heart attacks</span> and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span></span></p>
<p>Oral contraceptives may increase the tendency to develop <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span> (stoppage or 
rupture of blood vessels in the brain) and <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span> and <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attacks</span> 
(blockage of blood vessels in the heart). Any of these conditions can cause 
<span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> or <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span>.</p>
<p>Smoking greatly increases the possibility of suffering <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attacks</span> and 
<span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span>. Furthermore, smoking and the use of oral contraceptives greatly 
increase the chances of developing and dying of heart disease.</p>
<p>Women with <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> (especially <span class="product-label-link" type="condition" conceptid="381549" conceptname="Migraine with aura">migraine with aura</span>) who take oral 
contraceptives also may be at higher risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>.</p>
<p><span class="Bold">3. <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">Gallbladder disease</span></span></p>
<p>Oral contraceptive users probably have a greater risk than nonusers of having 
<span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">gallbladder disease</span>, although this risk may be related to pills containing high 
doses of estrogens.</p>
<p><span class="Bold">4. <span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">Liver tumors</span></span></p>
<p>In rare cases, oral contraceptives can cause benign but dangerous liver 
tumors. These benign <span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">liver tumors</span> can rupture and cause fatal internal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. 
In addition, a possible, but not definite, association has been found with the 
pill and liver cancers in two studies, in which a few women who developed these 
very rare cancers were found to have used oral contraceptives for long periods. 
However, liver cancers in general are extremely rare, and the chance of 
developing liver cancer from using the pill is thus even rarer.</p>
<p><span class="Bold">5. Cancer of the breast and reproductive organs</span></p>
<p>Breast cancer has been diagnosed slightly more often in women who use the 
pill than in women of the same age who do not use the pill. This small increase 
in the number of breast cancer diagnoses gradually disappears during the 10 
years after stopping use of the pill. It is not known whether the difference is 
caused by the pill. It may be that women taking the pill are examined more 
often, so that breast cancer is more likely to be detected. You should have 
regular breast examinations by a healthcare provider and examine your own 
breasts monthly. Tell your healthcare provider if you have a family history of 
breast cancer or if you have had breast <span class="product-label-link" type="condition" conceptid="4101098" conceptname="Nodule">nodules</span> or an abnormal mammogram.</p>
<p>Women who currently have or have had breast cancer should not use oral 
contraceptives because breast cancer is usually a hormone-sensitive tumor.</p>
<p>Some studies have found an increase in the incidence of cancer or 
precancerous lesions of the cervix in women who use oral contraceptives. 
However, this finding may be related to factors other than the use of oral 
contraceptives. There is insufficient evidence to rule out the possibility that 
the pill may cause such cancers.</p>
<p><span class="Bold">6. Lipid metabolism and <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> of the pancreas 
</span></p>
<p>In patients with inherited defects of lipid metabolism, there have been 
reports of significant elevations of plasma triglycerides during estrogen 
therapy. This has led to <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> in some cases.</p>
<p><span class="Bold">ESTIMATED RISK OF <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">DEATH</span> FROM A BIRTH CONTROL METHOD OR 
PREGNANCY</span></p>
<p>All methods of birth control and pregnancy are associated with a risk of 
developing certain diseases which may lead to <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span> or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. An estimate 
of the number of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> associated with different methods of birth control and 
pregnancy has been calculated and is shown in the following table.</p>
<a name="ibb987e3c-0199-46f7-8c61-c364740e6fd7"></a><table width="100%">
<caption><span>ANNUAL NUMBER OF BIRTH-RELATED OR METHOD-RELATED <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">DEATHS</span> ASSOCIATED WITH CONTROL OF FERTILITY PER 100,000 NONSTERILE WOMEN, BY FERTILITY CONTROL METHOD ACCORDING TO AGE </span></caption>
<tbody class="Headless">
<tr class="First">
<td><br></td>
<td><br></td>
<td><br></td>
<td>
<span class="Bold">AGE</span><br>
</td>
<td><br></td>
<td><br></td>
<td><br></td>
</tr>
<tr>
<td><span class="Bold">Method of control<br>and outcome<br></span></td>
<td>
<span class="Bold">15-19</span><br><br>
</td>
<td>
<span class="Bold">20-24</span><br><br>
</td>
<td>
<span class="Bold">25-29</span><br><br>
</td>
<td>
<span class="Bold">30-34</span><br><br>
</td>
<td>
<span class="Bold">35-39</span><br><br>
</td>
<td>
<span class="Bold">40-44</span><br><br>
</td>
</tr>
<tr>
<td>No fertility control methods<a href="#footnote-15">*</a>
</td>
<td>7.0<br>
</td>
<td>7.4<br>
</td>
<td>9.1<br>
</td>
<td>14.8<br>
</td>
<td>25.7<br>
</td>
<td>28.2<br>
</td>
</tr>
<tr>
<td>Oral contraceptives<br><span class="product-label-link" type="condition" conceptid="4222303" conceptname="Non-smoker">nonsmoker</span><a href="#footnote-16">†</a><br>
</td>
<td>0.3<br><br>
</td>
<td>0.5<br><br>
</td>
<td>0.9<br><br>
</td>
<td>1.9<br><br>
</td>
<td>13.8<br><br>
</td>
<td>31.6<br><br>
</td>
</tr>
<tr>
<td>Oral contraceptives<br>smoker<a href="#footnote-16">†</a><br>
</td>
<td>2.2<br><br>
</td>
<td>3.4<br><br>
</td>
<td>6.6<br><br>
</td>
<td>13.5<br><br>
</td>
<td>51.1<br><br>
</td>
<td>117.2<br><br>
</td>
</tr>
<tr>
<td>IUD<a href="#footnote-16">†</a>
</td>
<td>0.8<br>
</td>
<td>0.8<br>
</td>
<td>1.0<br>
</td>
<td>1.0<br>
</td>
<td>1.4<br>
</td>
<td>1.4<br>
</td>
</tr>
<tr>
<td>Condom<a href="#footnote-15">*</a>
</td>
<td>1.1<br>
</td>
<td>1.6<br>
</td>
<td>0.7<br>
</td>
<td>0.2<br>
</td>
<td>0.3<br>
</td>
<td>0.4<br>
</td>
</tr>
<tr>
<td>Diaphragm/spermicide<a href="#footnote-15">*</a>
</td>
<td>1.9<br>
</td>
<td>1.2<br>
</td>
<td>1.2<br>
</td>
<td>1.3<br>
</td>
<td>2.2<br>
</td>
<td>2.8<br>
</td>
</tr>
<tr class="Last">
<td>Periodic abstinence<a href="#footnote-15">*</a>
</td>
<td>2.5<br>
</td>
<td>1.6<br>
</td>
<td>1.6<br>
</td>
<td>1.7<br>
</td>
<td>2.9<br>
</td>
<td>3.6<br>
</td>
</tr>
</tbody>
</table>
<a href="http://SPLForm_DrugListing.xhtml#footnote-15">*</a>    <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> are birth related<br><a href="http://SPLForm_DrugListing.xhtml#footnote-16"></a><a href="http://SPLForm_DrugListing.xhtml#footnote-16">†</a>    <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> are method related<br><br><p>In the above table, the risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> from any birth control method is less 
than the risk of childbirth, except for oral contraceptive users over the age of 
35 who smoke and pill users over the age of 40 even if they do not smoke. It can 
be seen in the table that for women aged 15 to 39, the risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> was highest 
with pregnancy (7 to 26 <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> per 100,000 women, depending on age). Among pill 
users who do not smoke, the risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> was always lower than that associated 
with pregnancy for any age group less than 40. Over the age of 40, the risk 
increases to 32 <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> per 100,000 women, compared to 28 <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> associated with 
pregnancy in that age group. However, for pill users who smoke and are over the 
age of 35, the estimated number of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> exceeds those associated with 
pregnancy. If a woman is over the age of 40 and smokes, her estimated risk of 
<span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> is four times higher (117/100,000 women) than the estimated risk 
associated with pregnancy (28/100,000 women) in that age group.</p>
<p>The suggestion that women over 40 who don't smoke should not take oral 
contraceptives is based on information from older high-dose pills. An Advisory 
Committee of the FDA discussed this issue in 1989 and recommended that the 
benefits of oral contraceptive use by healthy, nonsmoking women over 40 years of 
age may outweigh the possible risks. Older women, as all women who take oral 
contraceptives, should take an oral contraceptive which contains the least 
amount of estrogen and progestin that is compatible with the individual patient 
needs. </p>
<p><span class="Bold">WARNING SIGNALS </span></p>
<p>If any of these adverse conditions occur while you are taking oral 
contraceptives, call your healthcare provider immediately:</p>
<ul>
<li>Sharp <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span> of blood, or sudden <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> 
(indicating a possible clot in the lung) 
</li>
<li><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> in the calf (indicating a possible clot in the leg) 
</li>
<li>Crushing <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> or heaviness in the chest (indicating a possible heart 
attack) 
</li>
<li>Sudden severe <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> or <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span>, disturbances of 
vision or speech, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, or <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> in an arm or leg (indicating a possible 
<span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>) 
</li>
<li>Sudden partial or complete <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span> (indicating a possible clot in the 
eye) 
</li>
<li><span class="product-label-link" type="condition" conceptid="80767" conceptname="Breast lump">Breast lumps</span> (indicating possible breast cancer or fibrocystic disease of 
the breast; ask your healthcare provider to show you how to examine your 
breasts) 
</li>
<li>Severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> or <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span> in the stomach area (possibly indicating a 
ruptured <span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">liver tumor</span>) 
</li>
<li>Difficulty in sleeping, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, lack of energy, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, or change in mood 
(possibly indicating severe <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>) 
</li>
<li><span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">Jaundice</span> or a yellowing of the skin or eyeballs, accompanied frequently by 
<span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, loss of appetite, dark-colored urine, or light-colored bowel 
movements (indicating possible liver problems) </li>
</ul>
<p><span class="Bold">SIDE EFFECTS OF ORAL CONTRACEPTIVES</span></p>
<p>In addition to the risks and more serious side effects discussed above (see 
<span class="Bold">RISKS OF TAKING ORAL CONTRACEPTIVES, ESTIMATED RISK OF <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">DEATH</span> 
FROM A BIRTH CONTROL METHOD OR PREGNANCY</span> and <span class="Bold">WARNING 
SIGNALS</span> sections), the following may also occur:</p>
<p><span class="Bold">1. Irregular <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span></span></p>
<p>Irregular <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> or spotting may occur while you are taking 
Loestrin 24 Fe Irregular <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> may vary from slight staining between 
menstrual periods to breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> which is a flow much like a regular 
period. Irregular <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> occurs most often during the first few months of oral 
contraceptive use, but may also occur after you have been taking the pill for 
some time. Such <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> may be temporary and usually does not indicate any 
serious problems. It is important to continue taking your pills on schedule. If 
the <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> occurs in more than one cycle or lasts for more than a few days, 
talk to your healthcare provider. </p>
<p><span class="Bold">2. Contact lenses</span></p>
<p>If you wear contact lenses and notice a change in vision or an inability to 
wear your lenses, contact your healthcare provider.</p>
<p><span class="Bold">3. <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid retention</span> or raised blood pressure</span></p>
<p>Oral contraceptives may cause <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> (<span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>) with <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the 
fingers or ankles and may raise your blood pressure. If you experience fluid 
retention, contact your healthcare provider.</p>
<p><span class="Bold">4. <span class="product-label-link" type="condition" conceptid="4264234" conceptname="Chloasma">Melasma</span> </span></p>
<p>A spotty darkening of the skin is possible, particularly of the face. The 
darkening may persist after stopping the pill.</p>
<p><span class="Bold">5. Other side effects</span></p>
<p>Other side effects may include <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, change in appetite, 
<span class="product-label-link" type="condition" conceptid="4208409" conceptname="Breast tenderness">breast tenderness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, loss of scalp 
hair, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginal infections</span>, and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>.</p>
<p>If any of these side effects bother you, call your healthcare provider.</p>
<p><span class="Bold">GENERAL PRECAUTIONS</span></p>
<p><span class="Bold">1. Missed periods and use of oral contraceptives before or 
during early pregnancy</span></p>
<p>There may be times when you may not menstruate regularly after you have 
completed taking a cycle of pills. If you have taken your pills regularly and 
miss one menstrual period, continue taking your pills for the next cycle but be 
sure to inform your healthcare provider. If you have not taken the pills daily 
as instructed and missed a menstrual period, or if you missed two consecutive 
menstrual periods, you may be pregnant. Check with your healthcare provider 
immediately to determine whether you are pregnant. Stop taking Loestrin 24 Fe if 
you are pregnant. </p>
<p>There is no conclusive evidence that oral contraceptive use is associated 
with an increase in <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> when taken inadvertently during early 
pregnancy. Previously, a few studies had reported that oral contraceptives might 
be associated with <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> but these studies have not been confirmed. 
Nevertheless, oral contraceptives should not be used during pregnancy. You 
should check with your healthcare provider about risks to your unborn child of 
any medication taken during pregnancy.</p>
<p><span class="Bold">2. While breastfeeding</span></p>
<p>If you are breastfeeding, consult your healthcare provider before starting 
oral contraceptives. Some of the drug will be passed on to the child in the 
milk. A few adverse effects on the child have been reported, including yellowing 
of the skin (<span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>) and <span class="product-label-link" type="condition" conceptid="78474" conceptname="Hypertrophy of breast">breast enlargement</span>. In addition, oral contraceptives 
may decrease the amount and quality of your milk. If possible, do not use oral 
contraceptives while breastfeeding. You should use another method of 
contraception since breastfeeding provides only partial protection from becoming 
pregnant, and this partial protection decreases significantly as you breastfeed 
for longer periods of time. You should consider starting oral contraceptives 
only after you have weaned your child completely.</p>
<p><span class="Bold">3. Laboratory tests</span></p>
<p>If you are scheduled for any laboratory tests, tell your healthcare provider 
you are taking birth control pills. Certain blood tests may be affected by birth 
control pills.</p>
<p><span class="Bold">4. Drug interactions</span></p>
<p>Certain drugs may interact with birth control pills to make them less 
effective in preventing pregnancy or cause an increase in breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. 
Such drugs include rifampin, drugs used for <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> such as barbiturates (for 
example, phenobarbital), carbamazepine (Tegretol<span class="Sup">®</span> is one 
brand of this drug), and phenytoin (Dilantin<span class="Sup">®</span> is one 
brand of this drug), primidone (Mysoline<span class="Sup">®</span>), topiramate 
(Topamax<span class="Sup">®</span>), phenylbutazone (Butazolidin<span class="Sup">®</span> is one brand), some drugs used for HIV such as ritonavir 
(Norvir<span class="Sup">®</span>), modafinil (Provigil<span class="Sup">®</span>) 
and possibly certain antibiotics (such as ampicillin and other penicillins, and 
tetracyclines). Pregnancies and breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> have been reported by 
users of combined hormonal contraceptives who also used some form of the herbal 
supplement St. John’s Wort. You may need to use a non-hormonal method of 
contraception during any cycle in which you take drugs that can make oral 
contraceptives less effective. Be sure to tell your healthcare provider if you 
are taking or start taking any other medications, including nonprescription 
products or herbal products while taking birth control pills.</p>
<p>You may be at higher risk of a specific type of liver dysfunction if you take 
troleandomycin (Tao<span class="Sup">®</span> capsules) and oral contraceptives at 
the same time.</p>
<p><span class="Bold">5. <span class="product-label-link" type="condition" conceptid="440647" conceptname="Sexually transmitted infectious disease">Sexually transmitted diseases</span></span></p>
<p>This product (like all oral contraceptives) is intended to prevent pregnancy. 
It does not protect against transmission of HIV (AIDS) and other sexually 
transmitted diseases such as Chlamydia, <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span>, <span class="product-label-link" type="condition" conceptid="198075" conceptname="Condyloma acuminatum">genital warts</span>, 
<span class="product-label-link" type="condition" conceptid="433417" conceptname="Gonorrhea">gonorrhea</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B, and <span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">syphilis</span>.</p>
<br><br>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-18"></a><p></p>
<p class="First"><span class="Bold">HOW TO TAKE Loestrin 24 Fe</span></p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a><p><span class="Bold">IMPORTANT POINTS TO REMEMBER</span></p>
<a href="http://"></a><a href="http://"></a><p><span class="Bold"><span class="Italics">BEFORE</span> YOU START 
TAKING YOUR PILLS:</span></p>
<ol>
<li>BE SURE TO READ THESE DIRECTIONS: 
<ul>
<li>Before you start taking your pills 
</li>
<li>Anytime you are not sure what to do </li>
</ul>
</li>
<li>TAKE ONE PILL EVERY DAY AT THE SAME TIME. <br>If you miss pills you could 
get pregnant. This includes starting the pack late. The more pills you miss, the 
more likely you are to get pregnant. 
</li>
<li>MANY WOMEN HAVE SPOTTING OR LIGHT <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">BLEEDING</span>, OR MAY FEEL SICK TO THEIR 
STOMACH WHILE TAKING THE FIRST 1 to 3 PACKS OF PILLS.<br>If you have spotting or 
light <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or feel sick to your stomach, do not stop taking the pill. The 
problem will usually go away. If it doesn't go away, check with your healthcare 
provider. 
</li>
<li>MISSING PILLS CAN ALSO CAUSE SPOTTING OR LIGHT <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">BLEEDING</span>, even if you take 
these missed pills. On the days you take 2 pills to make up for missed pills, 
you could also feel a little sick to your stomach. 
</li>
<li>IF YOU HAVE <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">VOMITING</span> (within 3 to 4 hours after you take your pill), you 
should follow the instructions for WHAT TO DO IF YOU MISS PILLS. IF YOU HAVE 
<span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">DIARRHEA</span> or IF YOU TAKE CERTAIN MEDICINES, including some antibiotics, or the 
herbal supplement St. John’s Wort, your pills may not work as well. Use a 
back-up method of birth control (such as condoms or spermicide) until you check 
with your healthcare provider. 
</li>
<li>IF YOU HAVE TROUBLE REMEMBERING TO TAKE THE PILL, talk to your healthcare 
provider about how to make pill-taking easier or about using another method of 
birth control. 
</li>
<li>IF YOU HAVE ANY QUESTIONS OR ARE UNSURE ABOUT THE INFORMATION IN THIS 
LEAFLET, call your healthcare provider. </li>
</ol>
<a href="http://"></a><a href="http://"></a><a href="http://"></a><p><span class="Bold"><span class="Italics">BEFORE  </span>YOU START 
TAKING YOUR PILLS</span></p>
<a href="http://"></a><a href="http://"></a><p>1. DECIDE WHAT TIME OF DAY YOU WANT TO TAKE YOUR PILL.<br>It is 
important to take it at about the same time every day.</p>
<p>2. LOOK AT YOUR PILL PACK: <br>Loestrin 24 Fe contains 24 "active" WHITE 
PILLS (with hormones) for WEEKS 1, 2, 3 and the first part of WEEK 4, and 4 
"reminder" BROWN PILLS (without hormones) for the last part of WEEK 4.</p>
<div class="Figure"><img alt="image of pill pack" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4cafa90a-9903-40d0-b8be-6ad78018b4b6&amp;name=pill%20pack.jpg"></div>
<p>3. ALSO FIND:</p>
<ul>
<li>where on the pack to start taking pills, 
</li>
<li>in what order to take the pills (follow the arrows), and 
</li>
<li>the week numbers as shown in the picture above. </li>
</ul>
<p>4. BE SURE YOU HAVE READY AT ALL TIMES: </p>
<ul>
<li>ANOTHER KIND OF BIRTH CONTROL (such as condoms or spermicide) to use as a 
back-up in case you miss pills. 
</li>
<li>AN EXTRA, PILL PACK. </li>
</ul>
<a href="http://"></a><a href="http://"></a><a href="http://"></a><p><span class="Bold">WHEN TO START THE <span class="Italics">FIRST</span> PACK OF PILLS</span></p>
<a href="http://"></a><a href="http://"></a><p>You have a choice of which day to start taking your first pack of 
pills. Decide with your healthcare provider which is the best day for you. Pick 
a time of day that will be easy to remember.</p>
<p>DAY-1 START:</p>
<ol>
<li>Pick the day label strip that starts with the first day of your period. 
(This is the day you start <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or spotting, even if it is almost midnight 
when the <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> begins.) 
</li>
<li>Place this day label strip on the tablet dispenser over the area that has 
the days of the week (starting with Sunday) printed on the plastic. 
</li>
<li>Take the first white pill of the first pack during the first 24 hours of 
your period. 
</li>
<li>You will not need to use a back-up method of birth control, since you are 
starting the pill at the beginning of your period. </li>
</ol>
<p>SUNDAY START:</p>
<ol>
<li>Take the first white pill of the first pack on the Sunday after your period 
starts, even if you are still <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. If your period begins on Sunday, start 
the pack that same day. 
</li>
<li>Use another method of birth control as a back-up method if you have sex 
anytime from the Sunday you start your first pack until the next Sunday (7 
days). Condoms or spermicide are good back-up methods of birth control. 
</li>
</ol>
<p>WHEN YOU SWITCH FROM A DIFFERENT METHOD OF HORMONAL CONTRACEPTION</p>
<ul>
<li>If your previous method had 28 pills, finish taking all 28 pills, then start 
taking Loestrin 24 Fe  on the day after the last pill. 
</li>
<li>If your previous method had 21 pills, finish taking all 21 pills, and wait 7 
days before starting Loestrin 24 Fe<span class="Bold">. </span>
</li>
<li>When you switch from a vaginal ring or skin patch, finish the 21 days of 
use, and wait 7 days after removal of the ring or patch before starting Loestrin 
24 Fe. 
</li>
<li>When you switch from a progestin-only pill, you should start Loestrin 24 Fe 
the next day. 
</li>
<li>When you switch from an implant or injectable contraceptive, you should 
start Loestrin 24 Fe on the day of implant removal or, if using an injectable 
contraceptive, the day on which the next injection would be due. </li>
</ul>
<a href="http://"></a><a href="http://"></a><a href="http://"></a><p><span class="Bold">WHAT TO DO DURING THE MONTH</span></p>
<a href="http://"></a><a href="http://"></a><ol>
<li>TAKE ONE PILL AT THE SAME TIME EVERY DAY UNTIL THE PACK IS EMPTY.<br>Do not 
skip pills even if you are spotting or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> between monthly periods or feel 
sick to your stomach (<span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>). <br>Do not skip pills even if you do not have sex 
very often. 
</li>
<li>WHEN YOU FINISH A PACK OF YOUR Loestrin 24 Fe:<br>Start the next pack on the 
day after your last brown "reminder" pill. Do not wait any days between packs. 
</li>
</ol>
<a href="http://"></a><a href="http://"></a><a href="http://"></a><p><span class="Bold">WHAT TO DO IF YOU MISS PILLS</span></p>
<a href="http://"></a><a href="http://"></a><p>Birth control pills may not be as effective if you miss any white 
pills, and particularly if you miss the first few or the last few white pills in 
a pack.</p>
<p><span class="Bold">If you MISS 1 white pill:</span></p>
<ol>
<li>Take it as soon as you remember. Take the next pill at your regular time. 
This means you may take 2 pills in 1 day. 
</li>
<li>You do not need to use a back-up birth control method if you have sex. 
</li>
</ol>
<p><span class="Bold">If you MISS 2 white pills in a row in WEEK 1 OR WEEK 2 of 
your pack:</span></p>
<ol>
<li>Take 2 pills on the day you remember and 2 pills the next day. 
</li>
<li>Then take 1 pill a day until you finish the pack. 
</li>
<li>You COULD BECOME PREGNANT if you have sex during the <span class="Italics">7 
days</span> after you restart your pills. You MUST use a non-hormonal birth 
control method (such as condoms or spermicide) as a back-up for those 7 days. 
</li>
</ol>
<p><span class="Bold">If you MISS 2 white pills in a row in WEEK 3 or Week 4 of 
your pack:</span></p>
<ol>
<li>
<span class="Bold">If you are a Day 1 Starter:<br></span>THROW OUT the rest of 
the pill pack and start a new pack that same day. <span class="Bold"><br>If you 
are a Sunday Starter</span>: <br>Keep taking 1 pill every day until 
Sunday.<br>On Sunday, THROW OUT the rest of the pack and start a new pack of 
pills that same day. 
</li>
<li>You may not have your period this month but this is expected. However, if 
you miss your period 2 months in a row, call your healthcare provider because 
you might be pregnant. 
</li>
<li>You COULD BECOME PREGNANT if you have sex during the <span class="Italics">7 
days</span> after you restart your pills. You MUST use a non-hormonal birth 
control method (such as condoms or spermicide) as a back-up for those 7 days 
after you restart your pills. </li>
</ol>
<p><span class="Bold">If you MISS 3 OR MORE white pills in a row at any 
time:</span></p>
<ol>
<li>
<span class="Bold">If you are a Day 1 Starter</span>:<br>THROW OUT the rest of 
the pill pack and start a new pack that same day. <span class="Bold"><br>If you 
are a Sunday Starter</span>:<br>Keep taking 1 pill every day until Sunday. 
<br>On Sunday, THROW OUT the rest of the pack and start a new pack of pills 
<br>that same day. 
</li>
<li>You may not have your period this month but this is expected. However, if 
you miss your period 2 months in a row, call your healthcare provider because 
you might be pregnant. 
</li>
<li>You COULD BECOME PREGNANT if you have sex on the days when you missed pills 
or during the first <span class="Italics">7 days</span> after restarting your 
pills. You MUST use a non-hormonal birth control method (such as condoms or 
spermicide) as a back-up the next time you have sex and for the first 7 days 
after you restart your pills. </li>
</ol>
<p><span class="Bold">If you forget any of the 4 brown "reminder" pills in Week 
4:</span></p>
<ol>
<li>THROW AWAY the pills you missed. 
</li>
<li>Keep taking 1 pill each day until the pack is empty. 
</li>
<li>You do not need to use a back-up method of birth control. </li>
</ol>
<p><span class="Bold">FINALLY, IF YOU ARE STILL NOT SURE WHAT TO DO ABOUT THE 
PILLS YOU HAVE MISSED: </span></p>
<ol>
<li>Use a BACK-UP METHOD of birth control anytime you have sex. 
</li>
<li>KEEP TAKING ONE WHITE PILL EACH DAY until you can reach your healthcare 
provider. </li>
</ol>
<p><span class="Bold">GENERAL </span></p>
<p><span class="Bold">1. Pregnancy due to pill failure</span></p>
<p>If taken every day as directed, the incidence of pill failure resulting in 
pregnancy is approximately 1% per year (one pregnancy per 100 women per year), 
but more typical failure rates are about 5% per year. If pregnancy does occur, 
the risk to the fetus is minimal.</p>
<p><span class="Bold">2. Pregnancy after stopping the pill</span></p>
<p>There may be some delay in becoming pregnant after you stop using oral 
contraceptives, especially if you had <span class="product-label-link" type="condition" conceptid="196168" conceptname="Irregular periods">irregular menstrual cycles</span> before you used 
oral contraceptives. It may be advisable to postpone conception until you begin 
menstruating regularly once you have stopped taking the pill and desire 
pregnancy.</p>
<p>There does not appear to be any increase in <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> in newborn babies 
when pregnancy occurs soon after stopping the pill.</p>
<p><span class="Bold">3. Overdosage</span></p>
<p>Serious ill effects have not been reported following ingestion of large doses 
of oral contraceptives by young children. Overdosage may cause <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and 
<span class="product-label-link" type="condition" conceptid="4161407" conceptname="Withdrawal bleeding">withdrawal bleeding</span> in females. In case of overdosage, contact your healthcare 
provider or pharmacist.</p>
<p><span class="Bold">4. Other information</span></p>
<p>Your healthcare provider will take a medical and family history before 
prescribing oral contraceptives and will examine you. The physical examination 
may be delayed to another time if you request it and the healthcare provider 
believes that it is a good medical practice to postpone it. You should be 
reexamined at least once a year. Be sure to inform your healthcare provider if 
there is a family history of any of the conditions listed previously in this 
leaflet. Be sure to keep all appointments with your healthcare provider, because 
this is a time to determine if there are early signs of side effects of oral 
contraceptive use.</p>
<p>Do not use this drug for any condition other than the one for which it was 
prescribed. This drug has been prescribed specifically for you; do not give it 
to others who may want birth control pills.</p>
<p><span class="Bold">HEALTH BENEFITS FROM ORAL CONTRACEPTIVES</span></p>
<p>In addition to preventing pregnancy, use of oral contraceptives may provide 
certain benefits. They are:</p>
<ul>
<li>Menstrual cycles may become more regular 
</li>
<li>Blood flow during menstruation may be lighter and less iron may be lost. 
Therefore, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> due to <span class="product-label-link" type="condition" conceptid="4146209" conceptname="Iron deficiency">iron deficiency</span> is less likely to occur 
</li>
<li><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> or other symptoms during menstruation may be encountered less 
frequently 
</li>
<li><span class="product-label-link" type="condition" conceptid="193530" conceptname="Follicular cyst of ovary">Ovarian cysts</span> may occur less frequently 
</li>
<li>Ectopic (tubal) pregnancy may occur less frequently 
</li>
<li>Noncancerous <span class="product-label-link" type="condition" conceptid="4209224" conceptname="Cyst">cysts</span> or lumps in the breast may occur less frequently 
</li>
<li>Acute <span class="product-label-link" type="condition" conceptid="199067" conceptname="Inflammatory disease of female pelvic organs AND/OR tissues">pelvic inflammatory disease</span> may occur less frequently 
</li>
<li>Oral contraceptive use may provide some protection against developing two 
forms of cancer: cancer of the ovaries and cancer of the lining of the uterus 
</li>
</ul>
<p>If you want more information about birth control pills, ask your healthcare 
provider or pharmacist. They have a more technical leaflet called the 
Professional Labeling, which you may wish to read.</p>
<p>Manufactured by: <br>Warner Chilcott Company, LLC<br>Fajardo, PR 
00738<br>Marketed by:<br>Warner Chilcott (US), LLC <br>Rockaway, NJ 
07866<br>1-800-521-8813</p>
<p><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Warner 
Chilcott at 1-800-521-8813 or FDA at 1-800-FDA-1088 or 
www.fda.gov/medwatch.</span></p>
<p>0530G035             Revised October 2009</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-19"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<br><p class="First"><img alt="image of package label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4cafa90a-9903-40d0-b8be-6ad78018b4b6&amp;name=package%20label.jpg"></p>
<p><span class="Bold">Loestrin<span class="Sup">®</span> 24 Fe</span></p>
<p>(norethindrone acetate and ethinyl estradiol tablets, USP and ferrous 
fumarate tablets)<br>1 mg/20 mcg</p>
<p>28-DAY REGIMEN </p>
<p>Loestrin<span class="Sup">®</span> 24 Fe  
provides 24 days of active therapy</p>
<p><br>Each pouch contains 1 blister card of 28 tablets.</p>
<p>PATIENT INSERTS are enclosed for your use when dispensing Loestrin<span class="Sup">®</span> 24 Fe  </p>
<p>Each white tablet contains norethindrone acetate, 1 mg;<br>ethinyl 
estradiol, 20 mcg; each brown tablet 
contains<br>ferrous fumarate 75 mg; each blister card contains <br>24 white tablets and 4 brown tablets.</p>
<p>Usual Dosage--One tablet daily for 28 days as directed<br>by the physician. See Package Insert for Full Prescribing Information. </p>
<p>This package is not child resistant.</p>
<p>Keep this and all drugs out of the reach of children.</p>
<p>Store at 25° C (77° F); excursions permitted to 15 - 30° C (59 - 86° 
F)<br>[see USP Controlled Room 
Temperature].<br>See bottom flap for lot number and expiration date.<br>Ferrous 
fumarate tablets are not USP for dissolution and assay.</p>
<p>To report SUSPECTED ADVERSE REACTIONS, contact Warner Chilcott at 
1-800-521-8813 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>LOESTRIN 24 FE 		
					</strong><br><span class="contentTableReg">norethindrone acetate and ethinyl estradiol, and ferrous fumarate kit</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-6100(NDC:0430-0530)</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-6100-0</td>
<td class="formItem">1  in 1 POUCH</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Quantity of Parts</td></tr>
<tr>
<th scope="col" width="5" class="formTitle">Part #</th>
<th scope="col" class="formTitle">Package Quantity</th>
<th scope="col" class="formTitle">Total Product Quantity</th>
</tr>
<tr class="formTableRowAlt">
<td width="5" class="formItem"><strong>Part 1</strong></td>
<td class="formItem"> </td>
<td class="formItem">24 </td>
</tr>
<tr class="formTableRow">
<td width="5" class="formItem"><strong>Part 2</strong></td>
<td class="formItem"> </td>
<td class="formItem">4 </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 1 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>LOESTRIN 24 FE 		
					</strong><br><span class="contentTableReg">norethindrone acetate and ethinyl estradiol, tablet</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-6100</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>NORETHINDRONE ACETATE</strong> (NORETHINDRONE) </td>
<td class="formItem">NORETHINDRONE ACETATE</td>
<td class="formItem">1 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>ETHINYL ESTRADIOL</strong> (ETHINYL ESTRADIOL) </td>
<td class="formItem">ETHINYL ESTRADIOL</td>
<td class="formItem">20 ug</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ACACIA</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SUCROSE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">6mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">WC;530</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021871</td>
<td class="formItem">01/28/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 2 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>INERT 		
					</strong><br><span class="contentTableReg">ferrous fumarate tablet</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-6100</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERROUS FUMARATE</strong></td>
<td class="formItem">75 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SUCROSE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">brown</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">6mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">PD;622</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021871</td>
<td class="formItem">01/28/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021871</td>
<td class="formItem">01/28/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">relabel</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 2/2010<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>7c74ca49-b7e0-4b27-91e7-132a2359a5dc</div>
<div>Set id: 4cafa90a-9903-40d0-b8be-6ad78018b4b6</div>
<div>Version: 1</div>
<div>Effective Time: 20100209</div>
</div>
</div> <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
